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Abstract 
 
A series of [Pt(diimine)(L
n
-O,S)]Cl complexes, where  L
n
-O,S represents a series of N,N-
dialkyl-N’-acylthiourea ligands and diimine represents (1,10-Phenanthroline; 5,6-dimethyl-
1,10-phenanthroline or [3,2-d:2’,3’-f]-quinoxaline were successfully synthesised and 
characterised. A new crystal structure was obtained for N,N-di(2-hydroxy)-N’-
benzoylthiourea which revealed an interesting herringbone crystal packing arrangement.  
The cytotoxicity of the series of complexes was evaluated on H1975 lung cancer cell lines at 
50 µM and 5 µM. All the complexes were highly cytotoxic with cell death of 90-98% at 50 
µM. However, at 5 µM there were much more variations on cell viability percentages. 
Although the structure–activity relationship can only be established when the IC50 (the 
concentration of an inhibitor where the response is reduced by half) values are determined, it 
is clear that the complexes containing the methyl substituents on the 5 and 6 positions of the 
phenanthroline moiety were the most cytotoxic with almost 98% cell death at 5 µM. The 
solubility of the complexes did improve by using N,N-dialkyl-N’-acylthiourea as ancillary 
ligands, however aqueous solubility remains a major problem.  
Sulphobutyl-ether-β-cyclodextrin (captisol) and low-molecular-weight surfactant micelles as 
drug delivery systems were considered in attempt to improve the solubility. DOSY NMR 
Spectroscopy revealed that there was no inclusion complex formation between the complex 
and capstiol, although the chemical shift trend suggested that there is at least some 
interaction. The low-molecular-weight surfactant micelles were considered as an alternative, 
which showed some promise as a drug delivery system, since the aqueous solubility 
improved and a colloidal suspension was obtained. 
 
iv 
 
 
 
 
 
 
 
 
 
 
 
And we know that God causes everything to work together for the good of 
those who love God and are called according to his purpose from them. 
Romans 8 vs 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
Acknowledgements 
 
I would like to express my gratitude to: 
 My Supervisor, Dr Izak Kotzé, whose expertise, understanding and patience added 
considerably to my project. I appreciate his vast knowledge and skills in many areas 
of my project. 
 Dr Juanita Van Wyk for all her assistance, time and valued advices throughout my 
project. 
 National Research Foundation and University of the Witwatersrand post-graduate 
merit award for funding. 
 All the staff and students in the Department of Chemistry. 
 The organometallic group, lab 122 for making the experience an enjoyable one. I met 
lifetime friends there. 
 My family and friends, for their support and encouragement throughout the 
completion of this degree. 
 Most importantly, I would like to thank my Lord and Saviour for the gift of life. 
 
 
 
 
 
 
 
 
vi 
 
Table of Contents 
 
 
Declaration ........................................................................................... ii 
Abstract ............................................................................................... iii 
Acknowledgements ............................................................................... v 
Table of Contents ................................................................................. vi 
List of Figures ..................................................................................... ix 
List of Tables ....................................................................................... xi 
List of Schemes and Diagrams ......................................................... xii 
List of Abbreviations ......................................................................... xiii 
Chapter 1 ...............................................................................................1 
Literature review: Platinum-based anticancer drugs .........................1 
1.1 Background on cancer and the current platinum anticancer drugs used ................................. 2 
1.1.1 Types of Cancer Treatment ............................................................................................. 2 
1.1.2 Current used platinum-based anticancer drugs ............................................................... 4 
1.1.3 Modes of reversible binding to DNA ..................................................................................... 5 
1.2 Square-planar metallodrugs .................................................................................................... 8 
1.3 N,N-alkyl-N’-acylthiourea as ancillary ligands ..................................................................... 11 
1.4 Drug-delivery Systems and Host-guest interactions ............................................................. 13 
1.4.1 Cyclodextrins as a drug delivery vehicle ...................................................................... 13 
1.4.2 Micelles as drug delivery vehicle .................................................................................. 16 
1.4.3 Host-guest interactions involved in drug delivery systems ........................................... 18 
1.5 Aims and Objectives of this study ........................................................................................ 21 
1.6 References ................................................................................................................................... 23 
Chapter 2 .............................................................................................28 
The synthesis and characterization of the ligands and complexes ..28 
2.1 Introduction ................................................................................................................................. 29 
2.2 Synthesis and characterization of N,N-di(alkyl)-N’-acylthioureas ............................................. 32 
vii 
 
2.2.1 Synthesis of N,N-di(alkyl)-N’-acylthioureas ........................................................................ 32 
2.2.2 Characterization of N,N-di(alkyl)-N’-acylthioureas ............................................................. 35 
2.2.3 X-ray crystallography of N,N-di(2-hydroxyethyl)-N’-benzoylthiourea (HL2) ..................... 39 
2.3 Synthesis and characterization of [PtCl2(diimine)] ..................................................................... 41 
2.4 Synthesis and characterization of [Pt(diimine)(L-O,S)]
+
complexes ........................................... 44 
2.5 Experimental Section .................................................................................................................. 51 
2.5.1 Materials and Instrumentation ............................................................................................. 51 
2.5.2 General procedure for the synthesis of N,N-di(alkyl)-N’-acylthiourea ................................ 51 
2.5.3 General procedure for the synthesis of [PtCl2(diimine)] ...................................................... 53 
2.5.4 General procedure for the synthesis of [Pt(diimine)(L-O,S)]
+
complexes ............................ 55 
2.5.5 X-ray crystallography of HL
2............................................................................................... 58 
Chapter 3 .............................................................................................61 
In Vitro Cytotoxicity Testing ..............................................................61 
3.1 Introduction ................................................................................................................................. 62 
3.2 MTT Assay to probe cytotoxicity ............................................................................................... 63 
3.3 Results and Discussion ............................................................................................................... 65 
3.4 Conclusion .................................................................................................................................. 68 
3.5 Experimental Section .................................................................................................................. 69 
3.6 References ................................................................................................................................... 71 
Chapter 4 .............................................................................................72 
Encapsulation of the [Pt(diimine)(L-O,S)]
+
 complexes with the 
Drug-delivery systems. ........................................................................72 
4.1 Introduction ................................................................................................................................. 73 
4.2 Encapsulation of [Pt(diimine)(L-O,S)]
+
complexes with captisol................................................ 75 
4.2.1 
1
H-NMR Spectroscopy studies of inclusion complex formation ......................................... 75 
4.2.2 DOSY NMR ......................................................................................................................... 79 
4.2.3 Micelles as a drug-delivery system ...................................................................................... 85 
4.3 Experimental Section .................................................................................................................. 87 
4.3.1 Instrumentation and Material ............................................................................................... 87 
4.3.2 Sample preparation for DOSY Spectroscopy ...................................................................... 87 
4.3.3 Methods of encapsulating the drug with the Captisol .......................................................... 87 
4.3.4 Methods of micellar formation ............................................................................................ 89 
4.4 Conclusion .................................................................................................................................. 89 
viii 
 
4.5 References ................................................................................................................................... 90 
Chapter 5 .............................................................................................92 
Summary and Conclusions ................................................................92 
APPENDIX .........................................................................................96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
List of Figures 
 
Figure 1.1  Position of the minor and major groove in the DNA double helix 
Figure 1.2 The two binding modes of metal complexes with DNA: (a) groove binding and 
(b) intercalation 
Figure 1.3 1,10-phenanthroline derivatives and chiral diimine ligands tested for cancer 
against L1210 mouse leukaemia 
Figure 1.4 General chemical structure of 1-(acyl/aryl)-3-substituted thioureas 
Figure 1.5 Most common coordination modes for monobasic O,S bidentate for dialkyl (A) 
and neutral monodentate through S atom (B) coordination modes for mono 
alkyl substituted thiourea 
Figure 1.6 The chemical structure (A) and the toroidal shape (B) of the α-cyclodextrin 
molecule 
Figure 1.7 Illustration of the hydrophobic and hydrophilic groups and the micelle 
formation 
Figure 1.8 Polymeric micelles showing the linkage present in polymeric micelles 
Figure 1.9     Structural variations of the series of [Pt(diimine)(L
n
-O,S)]Cl complexes to be 
synthesised 
Figure 2.1 Ligands synthesised with their full and abbreviated names 
Figure 2.2 
1
H NMR of HL
3
 in DMSO-d6 at 25 °C 
Figure 2.3 The COSY enlarged in the aliphatic region for HL
3
 in DMSO-d6 at 25 °C 
x 
 
Figure 2.4 
13
C NMR spectrum of HL
3
 in DMSO-d6 at 25 °C 
Figure 2.5 
1
H NMR of PtCl(5,6-dimethyl-1,10-phen) in DMSO at 25 °C 
Figure 2.6 [Pt(diimine)(L
n
-O,S)]Cl complexes synthesised with abbreviation of the names 
Figure 2.7 The 
1
H NMR of Pt(phen)(L
3
-O,S)]Cl  and the precursor [PtCl2(phen)]showing 
the loss of symmetry upon coordination of HL
3
 
Figure 2.8 
1
H COSY of [Pt(phen)(L
3
-O,S)]Cl in methanol-d4 at 25 °C where (a) aliphatic 
region (b) aromatic region 
Figure 2.9  
1
H NMR spectrum full assignment of [Pt(phen)(L
3
-O,S)]Cl in acetonitrile-d3 at 
25 °C 
Figure 3.1  The 96 well plates of the compounds tested with MTT assay at 50µM (left) and 
5 µM (right) 
Figure 3.2 MTT assay results for compounds tested with MTT assay and the % 
cytotoxicity at 5 µM 
Figure 4.1 Representation of the structure of captisol 
Figure 4.2  The 
1
H NMR of the pure complex (top) and inclusion complex (bottom). 
Figure 4.3 Attenuation of the 
1
H NMR of the mixture of inclusion complex, methanol, 
water during a typical DOSY experiment with the increasing gradient strength 
Figure 4.4 DOSY plot of a mixture of [Pt
II
(phen)(L-O,S)]
+
, methanol and water showing 
the diffusion coefficients 
 
xi 
 
List of Tables 
 
Table 2.1 Hydrogen –bond geometry (Å,°) for (SHELX) 
Table 2.2 Crystal structure experimental details of HL
2
 
Table 3.1 Percentage cytotoxicity of compound tested with MTT assay at 50 µM, along 
with the average mean and standard error 
Table 3.2 Percentage cytotoxicity of compound tested with MTT assay at 50 µM, along 
with the average mean and standard error 
Table 4.1 NMR chemical shifts of free complex and the complex in the inclusion complex 
Table 4.2 The diffusion coefficients of the inclusion complexes 
 
 
 
 
 
 
 
 
 
xii 
 
List of Schemes and Diagrams 
 
 
Scheme 2.1 The eight common synthetic routes for N,N-di(alkyl)-N’-cylthioureas: reaction 
(i) aninothiocarbonyl chloride with KCNS (ii )acylation of N,N-disubstitued 
thioureas (ii) N-acyl aminoimidoyl with H2S (iv) N-acylisothiorea with H2S (v) 
methyl-N-acylcarbomodithiated (vi)acyl isothiocynates (vii) aminothiocabonyl 
with R
3
CO2H (vii)hydrolysis of N-aminothiocarbonyl carbodiimides with 
mineral acids 
Scheme 2.2 Reaction scheme of the synthetic procedure used for the synthesis of N,N-
di(alkyl)-N’-acylthioureas 
Scheme 23 Reaction scheme for the synthesis of [PtCl2(diimine)] 
Scheme 2.4 Reaction scheme of the synthetic procedure of [Pt(phen)(L-O,S)]
+
complexes 
Diagram 2.1 ORTEP diagram showing the asymmetric crystal structure of N,N-di(2-
hydroxyethyl)-N’-benzoylthiourea 
Diagram 2.2 Packing diagram for compound 1 along the c-axes 
Scheme 4.1 Representation of the translation of molecule A and B 
 
 
 
 
 
xiii 
 
List of Abbreviations 
 
 
WHO  World Health Organization 
IARC  International Agency of Research on Cancer 
DNA  Deoxyribose Nucleic Acid 
RNA  Ribose Nucleic Acid 
JM216  cis, trans-[PtCl2(acetate)2(NH3)(cyclohexylamine)] 
AMD 473 cis-[PtCl2(NH3)(2-methylpyridine)] 
EIF3  eukaryotic initiation factor 3 
HET  2-hydroxythanethiolato 
terpy  2,2’,2”-terpyridine 
Uv-vis  ultra violet visible 
dppz  dipyrido[3,2-a:2’,3’-c]phenazine 
S,S-dach  1S,2S-diaminocyclohexane 
CpG  dinucleotide 
FDA  food and drug administration 
SBE  sulfobutyl ether 
DMSO  dimethylsulfoxide 
EPR  enhanced permeation and retention effect 
CMC  critical micellar concentration 
NMR  nuclear magnetic resonance 
NOESY nuclear overhauser effect spectroscopy 
ROESY rotating frame nuclear overhauser effect spectroscopy 
DOSY  diffusion ordered spectroscopy 
FT-IR  fourier transform infrared  
m.p  melting point  
xiv 
 
MeOH  methanol 
mol  moles 
ppm  parts per million 
FT-IR /IR fourier transform infrared spectroscopy 
dmp  5,6-dimethyl-1,10-phenanthroline 
dpq  [3,2-d:2’,3’-f] quinoxaline 
phen  phenanthroline 
CHNS  elemental analysis  
CD3CN acetonitrile 
MS  mass spectrometry 
MTT  3-(4-5-dimethylthioazol-2-yl)-2,5-diphenyl tetrazolium bromide 
EGFR  epidermal growth factor receptor 
ATP  adenosine triphosphate 
bpy  bipyridine 
MEOH methanol 
PFG  pulsed field gradient 
 
1 
 
 
 
 
 
 
 
 
Chapter 1 
Literature review: Platinum-based anticancer drugs 
 
 
 
 
 
 
 
 
2 
 
Chapter 1 
Literature review: Platinum-based anticancer drugs 
1.1 Background on cancer and the current platinum anticancer drugs used 
 
Worldwide, an estimate of 14.1 million new cases of cancer and 8.2 million cancer deaths 
was reported in 2012 by the World Health Organisation (WHO).
1 
It is estimated by The 
International Agency of Research on Cancer (IARC) that by 2030 the global burden will 
grow to 21.7 million new cancer cases and 13 million cancer deaths per annum, which will be 
attributed to the growth and ageing of the population. Cancer can be described as a group of 
diseases characterised by the uncontrolled growth and spread of abnormal cells.
2
 Usually, 
certain genes make sure that cells grow and produce in an orderly and controlled way, but 
from time to time a mutation happens in the gene when a cell divides. This result in a gene 
being damaged lost or copied twice. These cells than typically do not respond to signals to 
induce cell death (apoptosis) , and invade nearby tissues and spread throughout the body.
3
 In 
addition, cancer cells are very similar to normal cells and the immune system is not triggered 
to terminate them.   
1.1.1 Types of Cancer Treatment 
 
Even though cancer does not have a permanent cure, it can be treated by common therapies 
like surgery, chemotherapy and also radiotherapy.
4
 Surgery involves an operation to 
physically remove cancer cells while radiotherapy is the use of X-rays to kill the cancer cells. 
Chemotherapy involves the use of drugs to be taken orally or intravenously to kill the cancer 
cells.
4
 There are a wide range of chemotherapeutic drugs that are currently being used, which 
are grouped according to their mechanism of action, chemical structures and relationship to 
3 
 
other drugs. The types of the chemotherapeutic drugs include alkylating agents, 
topoisomerases inhibitors, mitotic inhibitors, corticosteroids and antimetabolites. Alkylating 
agents inhibit reproduction by damaging DNA by forming covalent bonds at two nucleophilic 
sites on different DNA bases to induce interstrand and/ or intrastrand cross-linking.
5,6
 The 
examples of alkylating agent include cisplatin, oxaliplatin and carboplatin. These drugs work 
in all phases of the cell cycle and are used to treat many different cancers, including cancers 
of the lung, breast and ovary. Topoisomerase inhibitors, on the other hand, are drugs that 
interfere with enzymes that are called topoisomerases which are responsible for separating 
the DNA strands so that they can be copied.
7
 There are also mitotic inhibitors which are 
derived from natural products which work by blocking cell division and corticosteroids which 
are natural hormones or hormones-like drugs that are useful in treating many cancer types by 
reducing inflammation and the immune response.
8
 
The majority of the current anticancer drugs target DNA or proteins overexpressed in tumour 
cells. It is worth mentioning that recently there has been a new advance in the anticancer 
drugs target, where they are looking at a new set of potential targets which include RNA 
intermediaries between DNA and proteins. A new way was discovered in which the human 
cells control cancer genes expression, at the step where the genes are translated into proteins. 
They potentially target messenger RNA where these tags binds with the eukaryotic initiation 
factor 3 (EIF3).
9
 A typical example of these drugs includes antimetabolites. Antimetabolites 
interfere with DNA and RNA growth by substituting for the normal building block of RNA 
and DNA.
5
 While the chromosomes are being copied the antimetabolites damages the cells.  
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1.1.2 Current used platinum-based anticancer drugs 
 
Even though the vast majority of pharmaceutical used for chemotherapy are based on organic 
molecules, a number of metal based pharmaceutical have also been discovered since the 
discovery of the platinum metallodrug, cisplatin. Cisplatin [Pt(NH3)2Cl2] was discovered by 
Barnet Rosenburg in the 1960’s in an attempt to understand whether electrical current played 
a role in cellular division. It was found that the phenomenon was not due to electric current 
but rather platinum hydrolysis products formed the inert platinum electrode.
10
 Later in the 
discovery, it was envisioned that cisplatin may be interesting to test for anticancer activity. 
When cisplatin was tested against 180 tumours in Swiss white mice, it demonstrated potent 
activity, shrinking large solid tumours and the mice survived and were healthy. After 6 
months, the cured mice did not show any signs of cancer.
10
 From the results obtained, 
cisplatin entered the clinical trial phase and has been used as an anticancer drug ever since 
and falls under the alkylating group of anticancer therapies.
10
 Cisplatin is able to cure over 
90% of testicular cancer and it plays a fundamental role in the treatment of cancers such as 
ovarian, head, neck, bladder, cervical, melanoma, lymphomas and many other types of 
cancers.
10
 However, despite its widely uses to treat cancer, its utility is limited by high 
toxicity, tumour resistance and relevant low solubility hence the drug cannot be administered 
orally.
11
 Due to these limitations of cisplatin, new anticancer drugs have been developed. Out 
of the many anticancer drugs that have been synthesized, only a few have been on the clinical 
trials and these include drugs such as Carboplatin, Oxaliplatin, JM216 ({cis, trans-
[PtCl2(acetate)2(NH3)(cyclohexylamine)]}) and AMD473 (cis-[PtCl2(NH3)(2-
methylpyridine)]) .
10
 These drugs have gained clinical approval because they possess at least 
one distinct clinical advantage over cisplatin. These advantages include activity against 
cancer with intrinsic or acquired resistance to cisplatin treatment, reduced toxic side effects 
and the ability to be administered orally.
10
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1.1.3 Modes of reversible binding to DNA 
 
 The DNA-targeted drugs interact with DNA in different ways namely intercalation, non-
covalent groove binding, covalent binding or cross-linking, DNA cleavage or nucleoside-
analog incorporation.
12
  These interactions are governed by 3 principal modes. The first mode 
includes controlling the transcription factors and polymerases, in which drugs interact with a 
protein that binds to DNA. The second mode is through RNA binding either to the DNA 
double helix to form nucleic acid triple helix structure or rather by exposing DNA single 
strand forming DNA-RNA hybrids that may interfere with transcriptional activity. The last 
mode includes the binding of small aromatic ligands molecules to DNA double helical 
structures.
12
  The binding of small aromatic ligands usually takes place through noncovalent 
interactions. There are five noncovalent interaction sites which include interaction with the 
DNA major groove, the interaction with the DNA minor groove, the intercalation between 
base pairs via the DNA minor groove, a threading intercalation mode and the electrostatic 
attraction with the anionic sugar-phosphate backbone of DNA.
13
 The groove binding is 
typically based on polyamines which are protonated under physiological conditions that 
strongly binds to the DNA. These molecules normally are crescent-shaped which bind to the 
major or minor groove of DNA based on the particular polyamine in addition to its overall 
charge.
14
 The minor groove is the part of DNA where backbones are close together in the 
double helix while major grooves are where the DNA backbones are far apart (Figure 1.1) . 
6 
 
 
Figure 1.1: Position of the Minor and Major groove in the DNA double helix.
15
 
The groove binding is stabilised by intermolecular interactions. This kind of binding does not 
bring large conformational changes in the DNA because it is just like the standard lock-and-
key model for ligand-macromolecular binding.
14
 The groove binding contains compounds 
which have unfused aromatic ring systems linked by bonds with a torsional freedom which 
then allows the molecules to adopt appropriate conformation to fit the helical curvature of the 
groove without so many changes to the DNA.  
 Electrostatic interactions on the other hand, typically involve metal cations such as Na
+
 or 
Mg
+
 since the stability of the folded DNA confirmations requires the interaction or ion-
pairing with such metal from the solution for a process called counterion condensation.
13
 The 
interaction between organic cationic molecules with DNA neutralises phosphate charges 
which then results in the release of condensed counterions. This is energetically favoured by  
providing an entropic contribution to the binding free energy.
16
 These organic cations have 
shown increased binding constants with decreasing salt concentration. The classical DNA 
intercalators, unlike the groove binders (Figure 1.2), are fused-ring aromatic molecules which 
could have positive charges on an attached chain or the ring system itself.
13
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(a) Groove binder                                       (b) Metallointercalator     
Figure1.2: The two binding modes of metal complexes with DNA: (a) groove binding and (b) 
intercalation
17
 
The intercalation occurs without even interfering with the hydrogen bonding of the base pairs 
and obeys the nearest neighbour exclusion principle.
18
 Moreover, when DNA is saturated 
with intercalators, every second potential intercalation site on the helix remains empty. For 
the intercalation to occur, the DNA base pairs need to separate 3.4 Å to form a cavity for the 
incoming planar ligands through the localised left-handed unwinding of the duplex. The B-
form DNA can twist at 36° (10 base pairs per one turn of 360°) for the DNA to accommodate 
the ligand, a reduction of this rotation occurs. Intercalation is believed to be due to the results 
of a hydrophobic interaction, whereby a hydrophobic aromatic molecule is drawn to a 
hydrophobic environment of the base pairs from the hydrophilic aqueous environment.
19
  
The other type of intercalation is the threading intercalation, whereby to the complex with 
DNA, an aromatic system is inserted between the base pairs, and you find that one cationic 
substituent binds in a major groove and the other binds in a minor groove.
20
 There is also 
another class of intercalation which is called the non-classical intercalation. This class of 
intercalation is based on the intercalators that are fused polyaromatic systems that have 
protonated nitrogen atoms or alternatively have protonated side chains attached to the ring 
8 
 
system.
13
 This binding is different from groove binding even though they both use 
polyaromatic molecules, the non-classical uses fused polyaromatic with protonated side 
chains while the groove binding uses unfused aromatic systems with terminal basic functions. 
In addition, the non-classical intercalators interact with DNA in a stereoselective manner, 
whereby the positive part of the polar aromatic system interacts with the DNA base pairs.
21
  
Recently intercalation has been found to be the mode of binding for many metallodrugs.  
1.2 Square-planar metallodrugs 
 
The intercalation of square-planar transition metal complexes as demonstrated by Jennette et 
al.  [Pt(terpy)S(CH2)2OH)]
+
 ([Pt(terpy)(HET)]
+
  where, terpy = 2,2’,2”-terpyridine and HET 
= 2-hydroxythenethiolato ligand, showed that these metallodrugs intercalate double-stranded 
DNA by using UV-vis, viscosity, circular dischroism, fluorescence displacement and 
unwinding experiments.
22
 Ligands like 1,10-phenanthroline and 2,2’-bipyridine have shown 
to intercalate DNA when incorporated into square-planar platinum complexes.
22
 However, 
when coordinated to non-square planar metals such as copper, the intercalation with DNA is 
much weaker due to the size of the intercalating ligand, although [Ru(phen)2dppz] where 
dppz=dipyrido[3,2-a:2’,3’-c]phenazine do intercalates strongly probably due to the large size 
of the intercalating ligand.
22
 Square–planar metallodrugs are of interest because they can bind 
DNA in a number of ways which include DNA binding via the major or minor grooves or by 
partial intercalation. Wang et al. showed that the platinum complex ([Pt(terpy)(HET)]
 +
) 
bound the DNA via the major groove as shown by  the crystal structure of a dinucleotide 
(CpG) with [Pt(terpy)(HET)]
+
.
22
 Collins et al. demonstrated that platinum metallodrugs 
which contain phenanthroline and phenantheraquinone diamine ligands, bound the 
oligonucleotide d(GTCGAC)2 via the minor groove of the DNA.
22
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Over the years, more attention has been drawn towards metallodrugs since they have shown 
to be active against cancer at much lower concentration than the alkylating agent, cisplatin.
23
 
Furthermore, they are also able effective against cisplatin-resistant cancer cell lines. Aldrich-
Wright and co-workers studied the structure-activity relationship of platinum intercalators 
with methylated phenanthroline intercalating ligand and chiral diamino ancillary ligands. 
They observed that [Pt(5,6-dimethyl-phen)(S,S-dach)]
2+
 where 5,6-dimethyl-phen = 5,6-
dimethyl-1,10-phenanthroline and S,S-dach = 1S,2S-diaminocyclohexane, was 12 times more 
cytotoxic than cisplatin for a wide range of cancer lines and showed excellent activity against 
cisplatin-resistant cancers.
23
 
Phenanthroline derivatives Pt complexes against L1210 mouse leukaemia cell line with the 
substitution of the methyl group in the 5 and 5,6 positions (Figure1.3) were also investigated 
by Brodie et al.; it was observed that these complexes with methyl groups in  these positions 
showed a significant increase in activity.
24
 5,6-dimethyl-1,10 phenanthroline was found to be 
100-fold more cytotoxic than cisplatin. This family of DNA intercalators also displayed 
excellent cytotoxicity in a number of human cancer cell lines, including some that are 
sensitive to cisplatin treatment and others that have one or more modes of resistance to 
cisplatin.
24
 Before the derivatives of 1,10-phenantroline ligand were discovered to be more 
active, phenanthroline complexes displayed potent cytotoxicity various cancer cell lines.
23
 
From these cytotoxicity tests, it was found that for high cytotoxicity the phenanthroline 
ligands should contain methyl groups in either the five or both five and six positions (Figure 
1.3) 
10 
 
Figure 1.3: 1,10-phenathroline derivatives and chiral diimine ligands tested  for cancer 
against L1210 mouse leukaemia. 
 
 Even though these Pt complexes with phenanthroline ligands have high activity against 
cancer, the aqueous solubility of such platinum(II) complexes is low and aggregate in 
solution as reported by Kotzé et al.
25
 Therefore one of the roles of the ancillary ligand is to 
improve the solubility of the complex. Ancillary ligands play an essential role in the 
development of the metal compounds as anticancer drugs. Ancillary ligands are incorporated 
to increase the stability of the metal centre, to change the kinetics of the complexes and also 
increase the selectivity of the complexes.
26
 In the rhodium compounds [Rh(L)2chrysi]
3+
 
where chrysi
3+
 = chrysene-5,6-dione diimine and L- bipyradine and 1,10-phenathroline 
ligand, the ancillary ligands had a significant effect in targeting DNA mismatches in vitro and 
in vivo.
27
. Hence, it is important to carefully choose the ancillary ligand since it plays an 
important role in the success of the drug design. Acylthioureas have been proved to be an 
excellent ancillary ligand and can be used to increase the solubility of platinum complexes.  
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1.3 N,N-alkyl-N’-acylthiourea as ancillary ligands 
 
Koch et al
28
 have shown that the inclusion of  hydroxy or amino functional groups in 
acylthioureas such as N-benzoyl-N’-N’-di(2-hydroxyethyl)thiourea and N-benzoyl-N’-N-bis-
diethylaminoethylthiourea drastically improves water solubility of the Pt complexes. 
N-N-alkyl-acylthioureas have gained much attention over the years as ligands for different 
metallodrugs due to their  diverse modes  of coordinating  to the metal centre and also due to 
the fact that they are easy to prepare.
29
 Thioureas can be described as compounds which 
contain the (>N-C(S)-N'<) functionality as shown in Figure 1.4, with the presence of O, N, N' 
and S donor atoms  which result in different coordination modes.
30
 
 
Figure 1.4: General chemical structure of 1-(acyl/aroyl)-3-substituted thioureas 
These molecules were first prepared by Neucki in 1871,
29
 and their coordination chemistry 
towards first-row transition metals have been investigated ever since. Thioureas may be 
mono-, di, tri or tetra substituted derivatives depending upon the extent of substitution on the 
nitrogen atoms. More specifically, acyl/aroyl substituted thioureas at (N’) have a carbonyl 
group bonded to the thiourea core. 
29
 Moreover, the substitution can also occur on the second 
nitrogen (N’) atom giving 1-(acyl/aroyl)-3(mono-substituted) and 1-(acyl/aroyl)-3,3(di-
substituted) thioureas with general formula R
1
C(O)NHC(S)N’R2R3  (Figure 1.4) , where R 
may be an alkyl, aryl or heterocyclic substituent. These molecules  have been  found to play 
an important role in the biological activity of a number of complexes.
31
 Moreover, 
acylthiourea  derivatives have been patented as antidiabetic, antiarthritic, antineoplastic and 
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anticoagulant agents and the potential use for the treatment of cognitive problems and 
prostrate disorder, herbicidal, fungicidal, bactericidal, insecticidal and plant growth regulator 
have also been shown.
32
   
It has been found that the presence of hard (O, N’and N) and soft donor sites (S) in these 
compounds offers a variety of coordination potential. The possible coordination modes 
include the bidentate coordination mode (L-O,S) with the loss of the NH proton.
33
 The 
monodentate coordination is via the S donor atom (L-S) which typically proceeds without the 
deprotonation (Figure 1.5). There are however, other coordination modes that have been 
reported which include the doubly deprotonated bridging mode (L-N: O, S).
33
 
 
(A)                                                            (B) 
Figure 1.5: Most common coordination modes for monobasic O,S bidentate for dialkyl (A ) 
and neutral monodentate through S atom (B) coordination mode for mono alkyl substituted 
thiourea. 
The N,N-alkyl-N’-acylthioureas show pronounced affinity to coordinate to different transition 
metals. Their ability to form metal chelates with various transition metals, specifically Ni(II), 
Cu(II), Pd(II), Co(II) and Pt(II) metal coordination takes place through the oxygen and 
sulphur atoms following deprotonation of the central nitrogen atom to yield predominately cis 
square-planar complexes. 
34
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Interestingly, the N,N-alkyl–N’-acylthiourea ligands can be used as an ancillary ligand to 
increase the water solubility of the insoluble drugs, since these ligands are reasonably soluble 
in water. Furthermore, hydroxyl groups can be introduced into the amine chain since the 
functionality of the amine chain can be easily changed, which may result in an increase in 
solubility of the ligand and the corresponding complex. However, the ancillary ligand is not 
completely acquitted and does affect the activity of the overall complex. Therefore, in certain 
cases, the more water soluble variation of the ancillary ligand results in a complex with lower 
activity and alternatives strategies such as drug delivery systems are required to improve 
solubility.
35
  
1.4 Drug-delivery Systems and Host-guest interactions  
 
Drug-delivery systems have the ability to improve the delivery and effectiveness of drugs and 
can sometimes reduce the cytotoxicity and improve drug metabolism.
36
 They are exerted in a 
controlled-release manner to prolong in vivo drug activity.
36
 There are a few molecular hosts 
that are typically used as effective drug delivery systems, which include cucurbit, 
calix[n]arenes, dendrimers, micelles and cyclodextrins. However, we will only focus on 
cyclodextrins and micelles in this study. 
1.4.1 Cyclodextrins as a drug delivery vehicle 
 
Cyclodextrins are often preferred due to their ability to form inclusion compounds with a 
large variety of molecules and also to discern various types of guest molecules by selectively 
incorporating molecules through size and polarity consideration.
35
 Furthermore, cyclodextrins 
are able to improve the aqueous solubility and chemical reactivity of many lipophilic drugs 
without changing their intrinsic ability to permeate lipophilic membranes.
35
 Cyclodextrins are 
made up of hydrophobic interior and hydrophilic exterior, which makes it possible for the 
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water insoluble drugs to insert into the hydrophobic interior via non-covalent association to 
the cyclodextrin, resulting in a host-guest complex with improved water solubility. 
Cyclodextrins possess  hydrophobic cavities which can be used as pharmaceutical excipients 
to improve the solubility, stability and bioavailability of hydrophobic and biomolecular 
drugs.
37
 Due to the lipophilic inner cavities and the hydrophilic outer surface of cyclodextrin 
(Figure 1.6), they are capable of interacting with a large variety of guest molecules to form 
non-covalent inclusion complexes.
38
 
 
Figure1.6: The chemical structure (A) and the toroidal shape (B) of the a-cyclodextrin 
molecule, (C) captisol structure.
39
 
There are three naturally occurring cyclodextrins namely; alpha (α), beta (β) and gamma (δ)-
cyclodextrin. These cyclodextrins differ in the ring size and solubility. β-cyclodextrins have 
been widely used in the early stage of pharmaceutical application because of its readily 
availability and cavity size suitable for the widest range of drugs.
38
 Over the past 30 years, 
the use of cyclodextrin has been considered to form inclusion complexes in order to increase 
the solubility of the insoluble drugs.
38
 This process is driven by both enthalpic and entropic 
energy contributions. The inclusion complexation helps to solubilize and stabilise drug 
molecules. Cyclodextrins that are successful in drug delivery are able to increase the 
permeability of drugs by increasing drug solubility which improves the bioavailability of the 
drug.
40
 Furthermore, increased drug solubility and mobility with cyclodextrins may reduce 
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drug toxicity by making the drug effective at lower doses. The cyclodextrin complexation 
also controls the drug release and in most cases allows the drug to be administered orally. 
The naturally occurring  cyclodextrins namely; the α and β-cyclodextrins are known to be 
parenterally unsafe due to the nephrotoxicity and low solubility, which led to the use of 
functionalised cyclodextrins. Functionalised sulfobutyl-ether-β-cyclodextrin commonly 
known as captisol have shown to overcome the limitations of β-cyclodextrins and have been 
used frequently in the past few years. Captisol was developed by The University of Kansas’ 
Higuchi Biosciences centre for specific use in drug development and formulation.
41
 Captisol 
is an anionic β-cyclodextrin derivative with a sodium sulfonate salt separated from the 
hydrophobic cavity by a butyl ether space group. The sulfobutyl ether (SBE) substituent is 
introduced at the 2, 3 and 6 positions in one or more of the glucopyranose units in the 
cyclodextrin mixture.
41
 Captisol is safe when administered parenterally in stark contrast to 
the nephrotoxicity exhibited by unmodified natural β-cyclodextrin. In addition, captisol is 
present in six FDA- approved products and there are also currently more than 50 captisol 
containing products in clinical development. 
Captisol is a successful drug delivery vehicle to many molecules that suffers from poor 
solubility and stability. Captisol has shown to complex neutral, cationic and anionic drugs 
and small and large molecules. The aqueous solubility of a complexed insoluble drug can 
increase by a factor of 10 to 25 000 depending on the compound.
41
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1.4.2 Micelles as drug delivery vehicle 
 
Similarly to cyclodextrins, micelles have the hydrophobic core which is sterically stabilised 
by a hydrophilic corona.
42
 Micelles are formed when surfactant molecules self-assemblies as 
shown in Figure 1.7.  
 
Figure 1.7: Illustration of the hydrophobic and hydrophilic groups and the micelle 
formation.
43
 
The core acts as a reservoir in which the drug molecule can be incorporated by different 
interaction namely the chemical, physical or electrostatic interaction depending on the 
physicochemical properties of the drug molecules.
42
 The micelles ability to solubilise the 
drug molecules helps in increasing the drug permeability across the physiologic barrier, 
protect the drug from inactivation by its biological surroundings, lower toxicity, and decrease 
the incidence and severity of adverse effect.
42
  
Micelles do not only solubilise hydrophobic drugs but they may also increase the systemic 
half-life of drugs and passively enhance their accumulation at the tumour site via enhanced 
permeation and retention (EPR) effect. Furthermore, micelles can also potentially improve 
the treatment efficacy by bypassing the drug resistance mechanism of multidrug resistance 
cells. There are two common types of micelles namely the low-molecular-weight surfactant 
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micelles and polymeric micelles. The micelle formation for low-molecular-weight surfactant 
may happen spontaneously in aqueous media or with the involvement of energy by heating at 
a specific temperature. At low concentrations in water (below the critical micellar 
concentration-CMC) amphiphilic molecules, with a hydrophobic moiety and a hydrophilic 
moiety orient themselves at the air-water interface and in the bulk disperse phase they exist as 
monomers.
44
 When the concentration of the amphiphiles reaches the CMC, the amphiphilic 
molecules aggregate in such a way that the hydrophobic moiety is shielded from the polar 
aqueous medium. In the case where there is no heat applied and the reaction happens at room 
temperature, the driving force is the entropy which increases from the release of water 
molecules adjacent to the hydrophobic moiety. In the case where the heat is needed, a 
specific temperature is required for micelle formation to occur. At the critical micellar 
temperature, the amphiphile is no longer soluble in the aqueous medium as a monomer. Once 
the monomers intrinsic solubility is exceeded, then micelle forming molecules proceed to 
aggregate and shield the hydrophobic moieties in the molecule from the aqueous disperse 
phase.
44
 On the polymeric micelles, the amphiphilic block or graft copolymers behave 
similarly to the conventional amphiphiles and aqueous solution. However, in polymeric 
micelles, there is a covalent linkage of individual surfactant molecules with the hydrophobic 
core in comparison to low-molecular-weight surfactants (Figure 1.8). 
 
Figure 1.8: Polymeric micelles showing the linkage present in polymeric micelles 
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In addition, the linkage present in polymeric micelles prevents a dynamic exchange of 
monomers between a free solution and the micellar pseudo-phase.
45
 Hence, the rigidity and 
stability to the polymeric micelles are conferred. There are different types of polymeric 
micelles which are characterised based on the type of intermolecular forces governing the 
segregation of the core segment from the aqueous environment. This includes conventional 
micelle and poly-ion micelles which result from the electrostatic interaction.
45
 The 
conventional micelles are based on the hydrophobic interactions between the core segment 
and the corona region in the aqueous environment. The poly-ion complex micelles, on the 
other hand, require an electrostatic interaction between two moieties such as polyelectrolytes 
that are oppositely charged in order to allow the formation of the polymeric micelles.
45
 
As previously stated, the development of micelles based–carriers of cancer chemotherapy 
have been a growing scientific interest as a result of the characteristics of micelles. Different 
micelles be it the low-molecular-weight surfactants micelles or polymeric micelles have been 
used to solubilize a range of anticancer drugs. It is undisputable that micelles offer great 
potential for the solubilisation and protection of poorly water-soluble anticancer drugs. 
1.4.3 Host-guest interactions involved in drug delivery systems 
 
To develop effective drug delivery systems involves an understanding of the interaction 
between the guest (drug) and host molecules (delivery system). Generally, a host is a 
molecule that contains a large cavity volume such as  cyclodextrins, micelles, cucurbituril or 
calixarenes and the guest typically has both a complementary shape and interaction with the 
host, which allows for selectivity with this host-guest match also known as molecular 
recognition.
46
 There are various non-covalent interactions that take place between the host 
and the guest and these includes the hydrogen bonding, electrostatic and Van der Waals 
interaction. Cyclodextrins and micelles form a great variety of host-guest complexes which 
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are also called an inclusion compound with the hydrophobic guest molecules typically 
encapsuslated in aqueous solution. 
The formation of the host-guest supramolecular complexes with cyclodextrin and an 
amphiphilic compound is driven by chemical, physical and electrostatic interactions.
47
 The 
formation of these host-guest complexes allows the controlling of  the assembly and 
disassembly of the supramolecular structure, by tuning the amphiphilicity of guest 
molecule.
47
 In aqueous solutions, the inclusion of the (dehydrated) guest into the non-polar 
cavity of the cyclodextrin is accompanied by the release of water from the cyclodextrin 
cavity. The latter process is strongly dependent on the interactions between water-water and 
water-cyclodextrin occurring inside the cyclodextrin cavity and it also depends on the other 
factors, including the size of the cyclodextrin cavity and guest as well as the structure 
(geometry) of guest molecules.
48
 
Many qualitative and quantitative methods have been used to study the host-guest 
interactions and these include NMR Spectroscopy, Titration Calorimetry, Potentiometry, UV-
Vis Spectrometry and Polarography. NMR Spectroscopy data can be used to determine the 
thermodynamic parameters, kinetic parameter and the host-guest complex conformation(s) 
using the two- dimensional (2D) NMR techniques. A correlation of the degree of molecular 
recognition with a structural feature of the host-guest complex is essential for understanding 
the origin of molecular recognition. Since molecular recognition involves a complicated 
steric fit between host and guest molecules, an understanding of molecular recognition 
requires a knowledge of the conformation of the complex.
49
 2D NOESY and ROESY NMR 
experiments provide information about the spatial distance between two protons as long as 
the motion of the molecule are not too fast for observation and the distance between the two 
hydrogens is shorter than 5Å.
49
 NMR is, therefore, an  excellent technique to study the host-
guest interactions because it doesn’t require any external probes or any modifications of 
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molecules under study and also the measurement are fairly quick and easy to perform since 
no pre-reaction is required.
50
 Diffusion-Ordered Spectroscopy (DOSY) NMR is also a useful 
to gain insight molecular dynamics, aggregation and conformational changes of the inclusion 
complex.  
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1.5 Aims and Objectives of this study 
 
There is a big drive for the development of better anticancer drug candidates that are soluble, 
more effective, less toxic and more selective. This class of complexes [Pt(diimine)(L-O,S)]
+
 
is believed to interact with DNA, since they have shown antibacterial activity and 
biomineralisation with DNA hence an investigation on the anticancer activity of these 
complexes is necessary due to the proposed DNA interactions . Therefore, the aims and 
objectives of this project were as follows: 
Aims: 
The aims of the project are: 
 To develop novel Platinum(II) complexes as potential anticancer agents. 
 To improve the solubility and cytotoxicity of the diimine complexes by using 
acylthiourea ancillary ligands and drug delivery systems. 
 To study the interaction between the drug delivery system and the Platinum(II) 
complexes. 
Objectives: 
In order to fulfil the aforementioned aims, the objectives were identified as follows: 
 Synthesis and characterization of ancillary ligands (Acylthioureas). 
 Synthesis and characterization of Pt(diimine)(Ln-O,S)Cl. 
22 
 
 
Figure 1.9: Structural variations of the series of [Pt(diimine)(L
n
-O,S)]Cl complexes to be 
synthesised. 
 In Vitro cytotoxicity testing. 
 Encapsulation of platinum (II) complexes in Sulphobutyl-ether-β- cyclodextrin. 
 NMR Spectroscopy study of the Host-guest interaction between the drug delivery 
system and the complexes. 
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Chapter 2 
The synthesis and characterization of the ligands and complexes 
2.1 Introduction  
 
In this chapter the synthesis of N,N-di(alkyl)-N’-acylthiourea metal complexes containing 
Pt(II) metal centre is described. It has been shown by Koch and co-workers that this 
[Pt(diimine)(L-O,S]Cl complexes as DNA intercalators have significant antimicrobial 
activity.
1
  Furthermore, this class of complexes have great potential as anticancer compounds 
since they can ion-pair with the negatively charged phosphate backbone of the DNA double 
helix and can potentially intercalate or bind to minor or major to the grooves of DNA.  
 There are several ways in which the N,N-di(alkyl)-N’-acylthioureas can be synthesised of 
which, the common routes used are shown in Scheme 2.1.  
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Scheme 2.1: The eight common synthetic routes for N,N-di (alkyl )-N’- cylthioureas: reaction 
(i) aninothiocarbonyl chloride with KCNS (ii) acylation of N,N-disubstitued thioureas (ii)  N-
acyl aminoimidoyl with H2S (iv) N-acylisothiorea with H2S (v) methyl-N-
acylcarbomodithiated (vi) acyl isothiocynates (vii) aminothiocabonyl with R
3
CO2H (vii) 
hydrolysis of N-aminothiocarbonylcarbodiimides with mineral acids. 
2
 
The most common method that is used and also will be used in this study to make these 
acylthioureas is the method described by Douglass and Dains,
3
 (as highlighted in scheme 2.1) 
which involves a simple "one-pot" procedure with generally good yields. These ligands tend 
to coordinate to the platinum group metals in two different modes namely the chelating mode 
(O, S) and the neutral monodentate (S).
4
 Due to these possible coordination modes, one of the 
problems with the synthesis of [Pt(diimine)(L-O,S)]
+ 
complexes is, one is most likely to form 
a mixture of products even on (1:1 mole ratio) of the [Pt(diimine)Cl2] and N,N-dialkyl-N’-
acylthiourea. This then requires a careful but tedious purification in order to obtain the 
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desired [Pt(diimine)(L-O,S)]Cl complexes. However, these complexes can be successfully 
synthesised. 
 The aim of this study was to synthesize potentially highly active anticancer agents based on 
Pt complexes, which have the basic structural formula [Pt(diimine)(acylthiourea)]Cl where, 
diimine represent various diimine ligands as potential intercalating ligands and N,N-dialkyl-
N’-acylthioureas as the ancillary ligand. 
The ligands, the metal precursor and the metal complexes were characterised using a range of 
techniques which includes NMR Spectroscopy, FT-IR Spectroscopy, Mass Spectrometry and 
Elemental Analysis. Single Crystal x-ray analysis of one of the ligands was also conducted.  
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2.2 Synthesis and characterization of N,N-di(alkyl)-N’-acylthioureas  
2.2.1 Synthesis of N,N-di(alkyl)-N’-acylthioureas 
  
The N,N–di(alkyl)-N’-acylthiourea were synthesised according to a modified procedure to the 
method described by Douglass and Dains,
3
 (Scheme 2.2). 
 
Scheme 2.2: Reaction scheme of the synthetic procedure used for the synthesis of N,N-
di(alkyl)-N’-acylthioureas3.
This method involves the addition of acyl chloride to a solution of potassium thiocyanate in 
dry acetone followed by 3 hours of heating under reflux and cooling to room temperature to 
yield the crude acyl isothiocyanate. The nucleophilic attack of the thiocyanate can either 
occur via the nitrogen or the sulphur. However, the latter product will revert to the desired 
acyl isothiocyanate intermediate which will react with the amine for 3 hours to form the 
desired product. A small volume of water was added to increase the rate of product 
precipitation and the mixture was placed in the vent of the fumehood to allow for evaporation 
of acetone to enhance crystal formation. Single product precipitates were recrystallized from 
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a combination of cyclohexane and ethyl acetate or purely hexane. Where the product failed to 
crystallise and oil was obtained, extraction into hexane was followed by separation and 
purification by column chromatography using silica gel. A series of these ligands (Figure 2.1) 
were synthesised using the above mentioned procedure. 
 
 
Figure 2.1: Ligands synthesised with their full and abbreviated names 
The hydroxyl containing ligands (HL
2 
& HL
5
) could not be easily crystallised and were 
purified by column chromatography. The pivaloyl containing ligand (HL
4
), however, was 
successfully crystallised from the water in the ice bath. The N,N-di(2-hydroxyethyl)-N’-
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acetylthiourea ligand was attempted with changes in the reaction conditions such as the use of 
hot acetone, acetonitrile and increase in the reaction time but it was found to be unsuccessful.  
The synthesised ligands were characterised by NMR Spectroscopy, FT-IR Spectroscopy, 
Elemental Analysis and Mass Spectrometry (See Experimental Section). One ligand is used 
to illustrate the characterization methodology.  
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2.2.2 Characterization of N,N-di(alkyl)-N’-acylthioureas  
 
The ligand HL
3
 was used to illustrate characterization methodology. The NMR assignments 
of the N,N-di(alkyl)-N-acylthioureas  was relatively simple. The 
1
H NMR spectrum of HL
3
 
exhibited a sharp singlet at 10.23 ppm which was identified as the NH proton. A sharp 
shielded singlet was observed at 1.95 ppm which integrated for 3 protons and was assigned to 
H
1
. 
 
 
Figure 2.2: 
1
H NMR of HL
3
 in DMSO-d6 at 25 °C. (Note: The break in horizontal scale between 
10.1 and 4.2 ppm. 
The triplets at 3.83 ppm and 3.35 ppm integrated for  2 protons each were assigned to H
a
 and 
H
a’
, due to electron withdrawing  nitrogen atom next to them , hence they are expected to be 
the most deshielded CH2 group. H
a
 was assigned as the most dishielded triplet based on the 
previous published results.
5
 The remaining multiplet within the ranges of 1.62-1.21 ppm 
N-H 
H
a 
H
1
 
H
b
  
H
d 
 
H
a’ 
H
c
  
H
b’
 H
c’
 
H
d’ 
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which were due to the CH2’s were assigned using the COSY (Figure 2.3). 
 
Figure 2.3:  The COSY enlarged in the alphatic region for HL
3
 in DMSO-d6 at 25 °C. 
The proton at 1.62 ppm which was overlapping with the one at 1.52 ppm was found to couple 
with H
a
 while the one at 1.52 ppm coupled with H
a’
 which enabled the assignment of H
b
 and 
H
b’. The proton at 1.33 pm coupled with Hb which then enable the assignment of Hc and 
consequently the assignment of H
c’
. The two overlapping triplets at 0.99 ppm and 0.88 ppm 
which integrated for 6 protons in total were assigned to H
d
 and H
d’
. The triplet at 0.99 ppm 
was found to couple with H
c 
while the triplet at 0.88 ppm coupled with H
c’
. 
 The C=S and C=O were assigned as the most deshielded carbons at 180.28 ppm and 166.789 
ppm. The C=S could be distinguished from the C=O based on the smaller intensity, which is 
a result of a broader signal for the C=S due to the quadrupolar relaxation caused by the bound 
14
N.
5
 The carbon that coupled to H
a
 was identified as the dieshielded carbon at 51.979 ppm 
and assigned as C
a
 while C
a’
 was found at 51.636 ppm respectively. The carbons due to the 
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CH3 were easily assigned using the DEPT NMR spectrum and also the C-H correlation, C
d
 
was found at 13.83 ppm while C
d’ 
was found at 13.68 ppm. The single bond correlation of H
1
 
with a carbon resonance at 22.982 ppm enabled the assignment of C
1
. HSQC was used to 
assign the remaining carbons. the multiple bond correlation of the protons H
b
, H
b
 and H
c
, H
c’
 
enabled the assignment of C
b 
and C
b’
 at 29.543 ppm and 27.874 ppm and also C
c
 and C
c’ 
to be 
at 19.356 ppm.  
 
Figure 2.4:  
13
C NMR spectrum of HL
3
 in DMSO-d6 at 25 °C. (Note: Two breaks in the 
horizontal scale between 34-48 ppm, 56-164 ppm and 172-178 ppm). 
The formation of the ligand was further confirmed by Infrared Spectroscopy which revealed a 
strong band at 1661.59 cm
-1
 (see Appendix), due to the C=O. The C=S stretch was observed 
at 1416.16 cm
-1
 and the NH stretch was found at 3166.93 cm
-1
. Furthermore, the Elemental 
Analysis data obtained for the ligands was found to be in agreement with the expected 
chemical composition. The chemical compositions of C, H, N and S were expected at 57.35, 
 
C=S 
C=O 
C
a C
b&b’ 
C
d
 
C
a’
 C
d’
 
C
c&c’
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9.63,12.16 and 13.92% respectively and  the analytical results were found to be 56.16 (C), 
9.36 (H), 12.25 (N) and 13.59% (S). Several crystals were obtained from the series of ligands 
but the crystal structure of HL
2
 has not been reported in literature before. 
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2.2.3 X-ray crystallography of N,N-di(2-hydroxyethyl)-N’-benzoylthiourea 
(HL
2
) 
 
The crystals of HL
2
 were isolated from a solvent mixture of cyclohexane and ethylacetate and 
these crystallised out in the P212121 space group with three molecular units per unit cell 
(Table 2.2). The atomic numbering of the structure is given in the ortep diagram below 
(Diagram 2. 1). 
 
Diagram 2 .1: ORTEP diagram showing the asymmetric crystal structure of N,N-di(2-
hydroxyethyl)-N’-benzoylthiourea. 
 
The compound exhibited both intramolecular interactions and intermolecular interactions, 
specifically hydrogen bond.  
The hydrogen bonds that resulted from compound included: O2B—H2B···S1 = 3.117 Å 
(intermolecular interaction), the above bonds can be confirmed from the Table 2.3 below. 
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Table 2.1 Hydrogen-bond geometry (Å, º) for (SHELX) 
D—H···A D—H H···A D···A D—H···A 
O2B—H2B···S1i 0.82 2.36 3.177 (3) 178 
C11—H11···O2B 0.97 2.54 3.104 (4) 117 
Symmetry code: (i) x−1, y, z. 
Table 2.1 above does confirm that there is intermolecular interaction taking place between 
S1—H2B-O2B, but again it also shows that there is an interaction between C11—H11---02B. 
This interaction between C11—H11---02B can be assigned as a weak hydrogen bond 
(intermolecular interaction) simply because of the directionality it possesses which are; the 
angle α is in the range between 90 to 180º, and the distance d is usually smaller than 3.2 Å. 
The unit cell packing of the compound was also investigated and it was extended to 3x3x3 to 
reveal the packing pattern. Compound 1 shown in Diagram 2.1 showed to have an a ribbon 
alignment in a herringbone fashion (Diagram 2.2) which is very common in aromatic 
molecules and this packing was due to the O2B-H2B…S1and C11-H11…O2B interaction.   
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Diagram 2.2: A view in project down the c axis of the unit-cell contents for compound 
1showing the packing 
 
2.3 Synthesis and characterization of [PtCl2(diimine)] 
 
The [PtCl2(diimine)] precursors were synthesised according to the procedure described by 
Morgan and Bustall.
6
 This method involved the addition of the phenanthroline derivatives to 
a solution of potassium tetrachloroplatinate in acidic water at room temperature (Scheme 
2.3). HCl was added to the reaction mixture to minimise the aquation of the [PtCl4]
2-
 species. 
The mixture was heated under reflux for 3 hours. A bright yellow precipitate was obtained for 
1,10-phenanthroline and 5,6-dimethyl-1,10-phenanthroline while [pyrazino(2,3-f)(1,10-
phenanthroline)] yielded an orange product. The product was washed several times with H2O 
to remove any unreacted tetrachloroplatinate followed by 3 aliquots of acetonitrile to remove 
42 
 
any unreacted diimine, using a centrifuge setup. The desired precursors were obtained in 
good yields (81-91%) and were characterised using 
1
H NMR Spectroscopy, FT-IR 
Spectroscopy, Mass Spectrometry and Elemental Analysis. 
 
Scheme 2.3: Reaction scheme for the synthesis of [PtCl2(diimine). 
6
 
The [PtCl2(dmp)]  where dmp= 5,6-dimethyl-1,10-phenanthroline complex is used to 
illustrate the characterization methodology. The 
1
H NMR spectrum of [PtCl2(dmp)] revealed 
4 sets of signals due to symmetry in the molecule (Figure 2.5).  
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Figure 2.5: 
1
H NMR of [PtCl2(dmp]) in DMSO at 25 °C (Note: the break in the horizontal scale 
between 3.5 and 7.5ppm) 
The most deshielded doublet of doublet at 9.10 ppm could be assigned to H
1 
and H
8
 due to its 
proximity to the nitrogen atoms.  Two doublets of doublet were observed, of which the one 
have shown a two large coupling constant which was assigned to H
7
 and H
2
, since they 
exhibit three-bond coupling (J
3
) to proton H
6
 and H
3
.The last doublet of doublet could be 
assigned H
3
 and H
6
 at 8.60 ppm because they will have a J
3 
coupling to H
2
 and H
7
 and a J
4
 
coupling to H
1 
and H
8
.  The CH3 (H
4
 and H
5
) were identified as singlet at 2.75 ppm, which 
integrated for 6 protons.  
The complex was also characterised by FT-IR Spectroscopy and the C=N stretch was found 
1616.62 cm
-1
, while aromatic C-H stretches was found at 122.17 cm
-1
. The Elemental 
Analysis of the complex was in agreement with the calculated C (35.46), H (2.55), and N 
(5.91) %. Analytical results were C (35.12), H (2.05) and N (5.88) %.  The complex with the 
H
1+8
 H
3+6
 H
2+7 
H
4+5 
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molecular weight of 474.24 g/mol. Different molecular masses were observed due to the 
isotopes from the chlorine (
35
Cl and 
37
Cl), also platinum (
195
Pt, 
197
Pt,
196
Pt and 
198
Pt). The 
masses were ionised by potassium and they were found to be 513.4, 515.2, 516.2, 517.2, 
518.2, 520.3 and 522.4 (See Appendix). All these results obtained confirmed the formation of 
[PtCl2(phen)] complexes. 
 
2.4 Synthesis and characterization of [Pt(diimine)(L-O,S)]
+
complexes 
 
The platinum complexes of N,N-di(alkyl)-N-acylthiourea were synthesised using a 
modification of the method described by Koch et al.
7 
(Scheme 2.3). One mole equivalent of 
[PtCl2(diimine)] was dissolved in acetonitrile and mixed with excess of sodium acetate. The 
reaction was heated under reflux for 30 minutes. One equivalent of the ligand was added in 
acetonitrile and the reaction mixture was further heated under reflux for 24 hours. The 
reaction mixture was then filtered in order to remove excess sodium acetate. The filtrate was 
then subjected to the rotary evaporator in order to remove the solvent until a highly 
concentrated solution mixture was obtained. The mixture obtained was subjected to diethyl 
ether to allow for selective precipitation of the complex and it was kept in the freezer 
overnight to maximise the yield. 
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Scheme 2.4: Reaction scheme of the synthetic procedure of [Pt(diimine)(L-O,S)]
+
complexes 
7
In the case of [PtCl2(dpq)] and [PtCl2(dmp)], the complexes were synthesized with some 
modifications to the general method. The [Pt(diimine)(L-O,S)]
+
 complexes were obtained by 
reacting the ligand and sodium acetate (1:2) in acetonitrile first to deprotonate the ligand. The 
reaction mixture was heated under reflux for one hour. One equivalent of the [PtCl2(diimine)] 
in acetonitrile was added and the reaction mixture was heated under reflux for 8 hours or 
longer depending on the ligand and the precursor. The solution was concentrated with a 
rotary evaporation and added to diethyl ether or hexane at -20 °C and stored in the freezer to 
allow for selective precipitation of the desired product. In the case of [Pt(dpq)(N,N-dibutyl-
N’-acylthiourea)] complex, a stronger base than sodium acetate, trimethylamine was used to 
deprotonate the ligand. In an attempt to synthesis the [Pt(phen)( N,N-di(2-hydroxyethyl)-N’-
acylthiourea)]
+
using different bases (Sodium acetate, Triethylamine) to deprotonate the 
ligands, and using different solvent combinations (diethyl ether, hexane, dichloromethane, 
chloroform and ethanol) to crystallise the desired complex (see Experimental Section), the 
synthesis was still found unsuccessful. The [Pt(phen)(N,N-di(2-hydroxyethyl)-N’-
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acylthiourea)] was attempted several times, even when the ligand was reacted with the base 
for 3 hours then adding the [PtCl2(phen)] to the reaction and running the reaction for 8 hours 
instead of overnight without success and is still subject to future study. 
The complexes that were successfully synthesised and characterised are shown in Figure 2.6. 
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Figure 2.6: [Pt(diimine)(L
n
-O,S)]Cl Complexes synthesised with abbreviation of the names. 
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2.2.3.1 
1
H–NMR, FT-IR and Mass spectrometry characterization of 
[Pt(phen)(L-O,S)]
+
 complexes  
 
The structural characterization of the [Pt(diimine)(L-O,S)]
+
 included NMR Spectroscopy, FT-
IR Spectroscopy, Mass Spectrometry. The 
1
H NMR showed the absence of the hydrogen due 
to the NH which indicated that the ligand was deprotonated. The proton due to the Pt 
precursor showed four sets of resonance signals due to the symmetry; however the 
synthesised complex showed all 8 sets resonance signals simply because the synthesised 
complexes had no plane of symmetry (Figure 2.7). 
 
Figure 2.7: The aromatic region 
1
H NMR of [Pt(phen)(L
3
-O,S)]Cl  and the precursor 
[PtCl2(phen)] showing the loss of symmetry upon coordination of HL
3
. 
 In order to assign the protons on the spectra obtained, several two-dimensional NMR 
experiments were conducted. The complex [Pt (phen)(L
3
-O,S)]Cl  will be used to illustrate 
the assignment of the 
1
H NMR. For the assignment to be made, an assumption that the 
 
 
H
1&8
 H
3&6 
H
4&5 
H
2&7 
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nitrogen trans to the sulphur atom is N’ and the most deshielded proton resonance signal is H1 
as proved by NOE data by Kotze et al.
8
 
Given the assumption made, the assignment of all the protons of [Pt
II
(phen)(L
3
-O,S)]Cl are 
possible using the correlations obtained from the COSY Spectrum (Figure 2.8). For clarity 
the aliphatic and aromatic region were enlarged in Figure 2.8a&b 
 
 
 
Figure 2.8: 
1
H COSY of [Pt(phen)(L
3
-O,S)]Cl in methanol-d4 at 25 °C where (a) aliphatic 
region (b) aromatic region. 
The protons H
4
 and H
5
 at 8.01 ppm were observed closely to each other but not overlapping 
due to the second order coupling were found and they were labelled H
4+5. 
Furthermore, there 
were no overlapping peaks for the phenanthroline that was observed. In order to make the full 
assignment of the complex [Pt (phen)(L
3
-O,S)]Cl, an assumption had to be made regarding 
the most deshielded proton. With these assumptions, full assignment of the proton spectrum 
were done as explained previously on the [PtCl2(diimine)] complexes using the 
1
H NMR  and 
COSY correlation. 
(a) 
(a 
(b) 
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Figure 2.9: 
1
H NMR spectrum full assignment of [Pt(phen)(L
3
-O,S)]Cl in acetonitrile-d3 at 
25 °C. (Note: the break on the horizontal scale between 5.4 and 7.7 ppm. 
The complexes were further characterised by FT-IR Spectroscopy, when characterised by FT-
IR it was observed that the full C=O and C=S stretching modes were no longer observed in 
the higher frequency stretching mode as they shift to lower frequency stretching modes. A 
typical semi C=O and C=S stretching modes were observed. The absence of the NH band in 
the FT-IR spectra of the metal complexes provided evidence that a bindate cationic complex 
was obtained. In the case of Mass Spectrometry (see apendix), it was observed that the parent 
ions for the complexes were observed as [M+K]
+
. In addition, all the isotopes of platinum 
and chlorine were observed
 
H
a+a
’ 
H
b+b’ 
 H
c+c’ 
 
 
H
d+d’’ 
H
2+7’ 
H
1 
H
4+5’ 
H
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H
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2.5 Experimental Section 
2.5.1 Materials and Instrumentation 
 
All reagents were commercially available and used without further purification. Acetone was 
dried with K2CO3 as a drying agent and distilled prior to use. Commercially available acyl 
chlorides, amines, and potassium thiocyanate were used to synthesise N,N-di(alkyl)-N’-
acylthiourea ligands. K2[PtCl4] from Sigma-Aldrich and SA Precious Metals with 
corresponding phenanthroline derivatives were used to synthesise the complexes. NMR 
experiments were performed on the Bruker Avance 300MHz and Bruker Avance III 500MHz 
respectively. The Infrared spectra were recorded on a Bruker FT-IR Spectrophotometer. Mass 
Spectrometry was performed using a Advion Expression L Compact. Elemental Analysis was 
performed using a Flash 2000 CHNS-O Analyser fitted with an auto sampler. 
2.5.2 General procedure for the synthesis of N,N-di(alkyl)-N’-acylthiourea 
 
The N,N-di(alkyl)-N’-acylthiourea were synthesised according to the method described by 
Douglass and Dains.
3
 The synthetic procedure is described using the synthesis of HL
1
 as an 
example. To a round-bottomed flask containing potassium thiocyanate (31.8 mmol) and dry 
acetone (75 ml), benzoyl chloride (30.8 mmol) was added. The resultant cloudy-white 
reaction mixture was heated to reflux for 3 hours and cooled to room temperature. A slow- 
dropwise addition of dibutylamime (30.8 mmol) followed and the resultant solution was 
heated under reflux for 3 hours. During this time a white-yellow solution formed. The 
reaction mixture was poured into 100 ml distilled water and kept overnight in a fumehood to 
evaporate some of the acetone to allow for crystallisation of the product. The N,N-di(alkyl)-
N’-acylthioureas were obtained as white to colourless solids in yields of 76- 96%. Several 
hydroxyl ligands were attempted with changes in the reaction conditions such as the use of 
hot acetone, acetonitrile and increase in the reaction time but it was found to be unsuccessful, 
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possibly due to several donor sites which could have led to different/ unwanted  coordination 
product. In attempting these ligands, different solvents were used; the reaction time was 
increased from 3hours to overnight reflux. When the reaction mixture was obtained, different 
ways to crystallise the ligands were attempted, however thick orange oil was obtained. When 
purified by column chromatography, the oil was still found not to be the desired compound. 
However, HL
2 
and HL
5 
were successfully synthesised but could not be crystallised hence they 
were purified by column chromatography (silica gel). Pivaloyl ligand (HL
4
), on the other 
hand, were successfully crystallised from the ice bath.  
The ligands were characterised using 
1
H, 
13
C NMR Spectroscopy, FT-IR Spectroscopy, Mass 
Spectrometry and Elemental Analysis.  
N, N-di(butyl)-N’-benzoylthiourea (HL1) : Yield 76% , m.p. 93-95 °C, 1H NMR (300 MHz, 
[d6] DMSO, 25 °C), δ(ppm) = 10.59 (s, 1H: NH),7.90 (m, 2H: H
1
,H
5
), 7.51(m, 2H : H
2
,H
4
), 
7.60 (tt, 1H: H
3
), 3.92 (t, 2H: H
a
), 3.44 (t, 2H: H
a’
), 1.70 (m(q), 2H: H
b
), 1.61 (m, 2H: H
b’
), 
1.37(m(h), 2H: H
c
), 1.21 (m(h), 2H: H
c’
), 0.94 (t, 3H: H
d
), 0.82(t, 3H: H
d’
) ; 
13
C NMR (300 
MHz, DMSO, 25 °C) δ(ppm) = 180.93 (C=S), 163.80 (C=O), 128.40 (C1,C5), 127.97 (C2,C4), 
132.19 (C
3
), 52.41 (C
a
), 51.60 (C
a’
), 29.74 (C
b
), 27.80 (C
b’
), 19.47 (C
c
), 19.35 (C
c’
), 13.75 
(C
d
), 13.45 (C
d’
), 132.96 (C
6). IR : ν(cm-1) 1372 (C=S), 1685.78 (C=O), 3166.93 (NH); 
elemental analysis calculated (%) for C16H24N2OS: C 65.71  H  8.27  N  9.58   S  10.96 , 
found : C 65.72  H  8.19  N  9.61  S  10.73. 
N, N-di(hydroxy)-N’-benzoylthiourea (HL2) : Yield 78% , m.p. 118-120 °C, 1H NMR (300 
MHz, [d6] DMSO, 25 °C), δ(ppm) = 10.87 (s, 1H: NH), 7.87(m, 2H: H
1
,H
5
), 7.50(m, 2H : 
H
2
,H
4
), 7.60 (tt, 1H: H
3
), 3.99 (t, 2H: H
a
), 3.77 (unres m , 6H: H
a’
, H
b
, H
b’
), H
b
), 5.66 (s, 1H: 
H
c
), 4.88 (t, 1H: H
c’
); 
13
C NMR (300 MHz, DMSO, 25 °C) δ(ppm) = 181.44 (C=S), 
164.465(C=O), 120.51 (C
1
,C
5
), 127.79 (C
2
,C
4
), 132.25 (C
3
), 55.03 (C
a
), 54.95 (C
a’
), 
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59.17(C
b
), 57.52 (C
b’
), 133.48 (C
6). IR : ν(cm-1) 1300.80 (C=S), 1693.83 (C=O), 3165.83 
(NH,OH); elemental analysis calculated (%) for C10H20N2O3S: C 53.71  H  6.01  N  10.44, 
found : C 53.69  H  5.93  N  10.39. 
N, N-di(butyl)-N’-acetylthiourea (HL3) : Yield 84% , m.p. 56-58 °C, 1H NMR (300 MHz, 
[d6] DMSO, 25 °C), δ(ppm) = 10.23 (s, 1H: NH),1.95 (s, 3H: H
1
), 3.83 (t, 2H: H
a
), 3.35 (t, 
2H: H
a’
), 1.62 (m(q), 2H: H
b
), 1.52 (m(q), 2H : H
b’
), 1.33(m, 2H: H
c
), 1.21 (m, 2H: H
c’
), 0.88 
(dt, 6H: H
d
 ,H
d’
); 
13
C NMR (300 MHz, DMSO, 25 °C) δ(ppm) = 180.28 (C=S), 166.79 
(C=O), 22.982 (C
1
), 51.979 (C
a
), 51.636 (C
a’
), 29.543 (C
b
), 27.874 (C
b’
), 19.470 (C
c
), 19.356 
(C
c’
), 13.678 (C
d
), 13.467 (C
d’
), 132.958 (C
6). IR : ν(cm-1) 1416.16 (C=S), 1661.59 (C=O), 
3166.93 (NH); elemental analysis calculated (%) for C11H22N2OS: C 57.35  H  9.63  N  12.16   
S  13.92 , found : C 56.61  H  9.36 N  12.25  S  13.59. 
N, N-di(butyl)-N’-pivaloylthiourea (HL4) : Yield 96% , m.p. 88-90 °C, 1H NMR (300 
MHz, [D6] DMSO, 25 °C), δ(ppm) = 10.23 (s, 1H: NH),1.95 (s, 9H: H1), 3.85 (t, 2H: Ha), 
3.31 (q, 2H: H
a’
), 1.63 (m(q), 2H: H
b
), 1.54 (m(q), 2H : H
b’
), 1.33(m, 2H: H
c
), 1.21 (m, 2H: 
H
c’
), 0.88 (dt, 6H: H
d
 ,H
d’
); 
13
C NMR (300 MHz, DMSO, 25 °C) δ(ppm) = 181.462 (C=S), 
174.7373 (C=O), 26.518 (C
1
), 52.451 (C
a
), 51.575 (C
a’
), 29.770 (C
b
), 27.814 (C
b’
), 19.421 
(C
c
, C
c’
), 13.730 (C
d
), 13.512 (C
d’
), 132.958 (C
6). IR : ν(cm-1) 1368.19 (C=S), 1654.13 
(C=O), 3302.58 (NH); elemental analysis calculated (%) for C14H28N2OS: C 61.72  H  10.36  
N  8.78  , found : C 61.73  H  10.72   N  10.28. 
2.5.3 General procedure for the synthesis of [PtCl2(diimine)] 
 
The platinum precursors were synthesised according to the method described by Morgan and 
Bustall et al.
6
 The synthetic procedure is described using the first precursor [Pt(1,10-
phenanthroline)Cl2 ] as an example. To a round-bottomed flask containing a solution of 
K2PtCl4 (0.3614 mmol) in 40 ml distilled water, an equivalent one molar of 1,10-
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phenanthroline was added and 6 drops of HCl were added. The reaction mixture was heated 
under reflux for 2 hours until a yellow precipitate was obtained. The reaction mixture was 
cooled to room temperature. The desired precursor was washed with acetonitrile and water 
via centrifuge system and dried under vacuum.  
The resultant products ware characterised by 
1
H NMR Spectroscopy, FT-IR Spectroscopy, 
Mass Spectrometry and Elemental Analysis. 
[PtCl2(1,10-phenanthroline)]: Yield 91.1%. 
1
H NMR (300MHz, [d6] DMSO, 25 °C) δ 
(ppm) = 9.71 (dd, 2H: H
1
, H
8
), 9.05 (dd, 2H: H
3
,H
6
), 8.30 (s, 2H: H
4
,H
5
), 8.17 (dd, 2H: 
H
2
,H
7); IR: ν(cm-1) 3057.16 (arom C-H), 1208.02 (arom C-C), 1627.05 (arom C=N); EIS (+) 
Mass Spectrometry ,485.1,[PtCl2(phen)]; elemental analysis (%) calculated for C12H8Cl2N2Pt 
C  32.30   H  1.81  N 6.28 ; found : C  32.16   H  1.72    N  6.27.  
[PtCl2(5,6-dimethy-1,10-phenanthroline)]: Yield 81.8%. 
1
H NMR (300MHz, [d6] DMSO, 
25 °C) δ (ppm) = 9.10 (dd, 2H: H1, H8), 8.70 (dd, 2H: H3,H6), 7.75(dd, 2H: H2,H7), 2.75  (s, 
6H: H
4
,H
5); IR: ν(cm-1) 3077.46 (arom C-H), 1222.17 (arom C-C), 1616.62 (arom C=N); EIS 
(+) Mass Spectrometry ,513,[PtCl2(dmp)]; elemental analysis (%) calculated  for 
C14H12Cl2N2Pt C  35.46   H  2.55  N 5.91 ; found : C  35.12   H  2.05    N  5.88.  
[PtCl2(pyrazino(2,3-f)(1,10-phenanthroline)]: Yield 90.4%. 
1
H NMR (300MHz, [d6] 
DMSO, 25 °C) δ (ppm) = 9.50 (dd, 2H: H1, H8), 9.25 (dd, 2H: H3,H6), 9.20 (s, 2H: H4,H5), 
8.00 (dd, 2H: H
2
,H
7); IR: ν(cm-1) 3078.63 (arom C-H), 1213.99 (arom C-C), 1613.37 (arom 
C=N); EIS (+) Mass Spectrometry,537.0,[PtCl2(dpp)] elemental analysis (%) calculated for 
C14H12Cl2N2Pt C  33.75   H  1.62  N 11.24 ; found : C  34.62   H  1.65    N  11.28.  
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2.5.4 General procedure for the synthesis of [Pt(diimine)(L-
O,S)]
+
complexes 
 
A suspension of [Pt(diimine)Cl2] (33.6 mmol) and excess sodium acetate (67.2 mmol) in 40 
ml acetonitrile was heated under reflux for 30 minutes . An appropriate N,N-di(alkyl)-N’-
acylthiourea in 10 ml of acetonitrile was heated under reflux overnight. The resultant yellow- 
orange mixture was filtered to remove any unreacted sodium acetate. The filtrate was 
concentrated by the evaporation of the solvent. The concentrated solution was added to 
diethyl ether (20 ml) and left in the freezer overnight. The resultant precipitate from diethyl 
ether was added to dichloromethane and filtered to remove unreacted sodium acetate that 
may be remaining. The filtrate was again concentrated and added to diethyl ether and re-
suspended several times. The yellow product was dried for 5-10 hours under vacuum.  
The successful resultant products were characterised by 
1
H NMR Spectroscopy, 2D NMR 
Spectroscopy, FT-IR Spectroscopy and Mass Spectrometry. 
[Pt(phen)(L
1
-O,S)]Cl : 
1
H NMR (300MHz,[d3]CD3CN, 25 °C) δ(ppm) = 9.28 (d, 1H: H
1
), 
8.95 (d, 1H: H
8
), 8.87(td, 2H: H
4
,H
5
), 8.20 (unres aromatic, 5H: H
9
,H
10
,H
11
,H
12
,H
13
), 
7.96(m(ddd) ,1H: H
3
), 7.69(m, 1H: H
6
), 7.55(td, 2H: H
2
,H
7
), 3.86(m, 4H: H
a
,H
a’
), 1.90(m, 
2H: H
b
), 1.76(m, 2H: H
b’
), 1.57(m, 2H: H
c
), 1.47(m, 2H: H
c’
), 1.12(td, 3H: H
d
), 1.02(td, 3H: 
H
d’); IR:ν(cm-1) 1203.98 (C-S), 1368.96 (C-O); ESI (+) Mass 
Spectromentry,667.3,[Pt(phen)(L
1
-O,S)]
+
 
[Pt(phen)(L
3
-O,S)]Cl : 
1
H NMR (300MHz,[d3]CD3CN, 25 °C) δ(ppm) = 9.07(dd, 1H: H
1
), 
8.95 (dd, 1H: H
8
), 8.90 (dd, 1H: H
3
), 8.82 (dd , 1H: H
6
),8.20(m, 3H: H
4
,H
5
,H
2
), 7.99(dd, 1H: 
H
7
), 2.28 (s, 3H: H
9
), 3.83(m, 2H: H
a
), 3.83(m, 2H: H
a’
) 1.87 (m, 2H: H
b
), 1.72 (m, 2H: H
b’
), 
1.55(m(h), 2H: H
c
), 1.44 (m, 2H: H
c’
), 1.11(t, 3H: H
d
), 1.03(t, 3H: H
d’); IR:ν(cm-1) 1259.00 
(C-S), 1369.00 (C-O); ESI (+) Mass Spectromentry,605.3,[Pt(phen)(L3-O,S)]+ 
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[Pt(phen)(L
4
-O,S)]Cl : 
1
H NMR (300MHz,[d3]CD3CN, 25 °C) δ(ppm) = 9.35 (dd, 1H: H
1
), 
9.27 (m, 1H: H
8
), 8.97(m, 2H: H
4
,H
5
), 8.25(m, 3H: H
3
,H
6
,H
2
), 8.03(m, 1H: H
7
), 1.90(s, 9H: 
H
9
), 3.93(m, 2H: H
a
), 3.84(m, 2H: H
a’
) 1.73(m, 2H: H
b
), 1.56(m, 2H: H
b’
), (m, 2H: H
c
), (m, 
2H: H
c’
), 1.10(td, 3H: H
d
), 1.02(td, 3H: H
d’); IR:ν(cm-1) 1220.00 (C-S), 1431.00 (C-O); ESI 
(+) Mass Spectromentry,647.2,[Pt(phen)(L
4
-O,S)]
+
 
 [Pt(dmp)(L
1
-O,S)]Cl : 
1
H NMR (300MHz,[d3]CD3CN, 25 °C) δ(ppm) = 9.15 (d, 2H: 
H
1
,H
8
),9.06(d, 1H: H
3
),8.83 (d, 1H: H
6
), 8.34(dd, 1H: H
2
), 8.15(m, 2H: H
9,
H
13
), 8.03(dd, 1H: 
H
7
), 7.72(t, 1H: H
11
), 7.58(t, 2H: H
10
,H
12
) 2.74(d, 6H: H
4
,H
5
) 3.85(m(q), 4H: H
a
,H
a’
), 1.84(m, 
2H: H
b
), 1.67(m, 2H: H
b’
), 1.50(m(q), 2H: H
c
), 1.39(m(q), 2H: H
c’
), 1.05(t, 3H: H
d
), 
0.95(t,3H: H
d’
); IR:ν(cm-1) 1216.99 (C-S), 1397.17 (C-O); ESI (+) Mass 
Spectromentry,695.3,[Pt(dmp)(L
1
-O,S)]
+
 
[Pt(dmp)(L
3
-O,S)]Cl : 
1
H NMR (300MHz,[d3]CD3CN, 25 °C) δ(ppm) = 9.08 (m, 2H: H
1
, 
H
8
), 8.99 (d, 1H: H
3
), 8.73(d, 1H: H
6
), 8.20(dd, 1H: H
2
), 8.02(dd, 1H: H
7
), 2.80(d, 6H: H
4
,H
5
) 
, 2.29(s,3H: H
9
), 3.84(t, 2H: H
a
),3.75(t, 2H: H
a’
) 1.81(m, 2H: H
b
), 1.64(m(p), 2H: H
b’
), 
1.50(m(p), 2H: H
c
), 1.34(m(q), 2H: H
c’
), 1.03(t, 3H: H
d
), 0.95(t, 3H: H
d’); IR:ν(cm-1) 1208.13 
(C-S), 1422.96 (C-O); ESI (+) Mass Spectromentry,633.1,[Pt(dmp)(L3-O,S)]+ 
 [Pt(dmp)(L
4
-O,S)]Cl : 
1
H NMR (300MHz,[d3]CD3CN, 25 °C) δ(ppm) = 9.12 (d,1H: H
1
), 
8.99 (d,1H: H
8
), 8.91(d,1H: H
3
) 8.81(d,1H: H
6
), 8.15(dd,1H: H
2
), 7.89(dd,1H:H
7
), 2.80(d,6H: 
H
4
,H
5
) , 1.39(s,9H: H
9
), 3.88(m,2H: H
a
),3.80(m,2H:H
a’
) 1.75(m,2H: H
b
), 1.75(m,2H: H
b’
), 
1.54(m,2H: H
c
), 1.54(m,2H: H
c’
), 1.09(t,3H:H
d
), 0.99(t,3H: H
d’); IR:ν(cm-1) 1221.76 (C-S), 
1359.13 (C-O); ESI (+) Mass Spectromentry,675.3,[Pt(dmp)(L
4
-O,S)]
+
 
[Pt(dpq)(L
1
-O,S)]Cl : 
1
H NMR (300MHz,[d3]CD3CN, 25 °C) δ(ppm) = 9.70 (d, 1H: H
1
), 
9.61(d, 1H: H
8
), 9.14(s, 2H: H
4
,H
5
), 8.87 (d, 1H: H
3
), 8.37(m, 2H: H
2
,H
7
), 8.00(d, 3H: 
H
6
,H
9
,H
13
), 7.64(d, 1H: H
11
), 7.48(t, 2H: H
10
,H
12
) ,3.78(m, 4H: H
a
,H
a’
), 1.70(m, 4H: H
b
,H
b’
), 
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1.57(m, 4H: H
c
,H
c’
), 1.11(t, 3H: H
d
), 1.01(t, 3H: H
d’); IR:ν(cm-1) 1222.00 (C-S), 1383.12 (C-
O); ESI (+) Mass Spectromentry,719.2,[Pt(dpq)(L
1
-O,S)]
+
 
 [Pt(dpq)(L
3
-O,S)]Cl : 
1
H NMR (300MHz,[d3]CD3CN, 25 °C) δ(ppm) = 9.81 (dd, 1H: H
1
), 
9.75(dd, 1H: H
8
), 9.26(dd, 2H: H
4
,H
5
), 8.91 (dd, 1H: H
3
), 8.33(dd, 1H:H
6
), 8.10(dd ,2H: 
H
2
,H
7
) 3.65(m, 4H: H
a
,H
a’
), 1.70(m, 4H: H
b
,H
b’
), 1.50(m, 2H: H
c
), 1.40(m, 2H: H
c’
), 1.11(t, 
3H: H
d
), 1.00(t, 3H: H
d’); IR:ν(cm-1) 1304.08 (C-S), 1381.53 (C-O); ESI (+) Mass 
Spectromentry,657.3,[Pt(dpq)(L
3
-O,S)]
+
 
 [Pt(dpq)(L
4
-O,S)]Cl : 
1
H NMR (300MHz,[d3]CD3CN, 25 °C) δ(ppm) = 9.82 (d, 1H: H
1
), 
9.76(d, 1H: H
8
), 9.47(dd, 1H: H
3
), 9.39(s, 2H: H
4
,H
5
), 9.24(dd, 2H: H
2
,H
7
), 7.96(dd, 1H: H
6
), 
1.35(s, 9H: H
9
) 3.89(m, 2H: H
a
), 3.78(m, 2H: H
a’
), 1.83(m, 2H: H
b
), 1.66(m, 2H: H
b’
), 
1.50(m(q), 2H: H
c
), 1.50(m(q), 2H: H
c’
), 1.03(t, 3H:H
d
), 0.94(t, 3H: H
d’); IR:ν(cm-1) 1222.73 
(C-S), 1382.08 (C-O); ESI (+) Mass Spectromentry,699.1,[Pt(dpq)(L4-O,S)]+ 
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2.5.5 X-ray crystallography of HL
2 
 
The Bruker SMART II CCD area detector diffractometer with a graphite monochromated 
Mok/a radiation (50Kv,30 m A) was  used to collect all the intensity data. Crystal structures 
of N,N-di(2-hydroxyethyl)-N’-benzoylthiourea were collected at 296 K. The collection 
method involved ɷ- scans of width 0.3. Data reduction was carried out using the program 
SAINT. The crystal structures were solved in the WINGX suite of programs by direct 
methods using SHELXS- Gui Control. The structures were then refined by least-squares on 
weighted F2 value for all reflections. All non-hydrogen atoms were refined with anisotropic 
displacement parameters hence the hydrogen atoms attached to N and O atoms were located 
in the difference Fourier map and their coordinates refined freely with isotropic parameters 
1.5 times those of the "heavy" atoms to which they are attached. All the C-H hydrogen atoms 
were placed at an idealised position and refined as riding atoms with isotropic parameters 1,2 
times those of the “heavy” atoms to which they are attached. Diagrams and publication 
material were generated using ORTEP-3, and PLATON (11 & 12). Experimental details of 
the X-ray analysis are provided in Table 2.2.  
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Table 2.2: Crystal experimental details of HL
2
 
Crystal data 
Chemical formula                 C12H16N203S 
Mr                 268.33 
Crystal system, space 
group 
                Orthorhombic, P212121 
Temperature (K)                 296 
a, b, c (Å)                 7.3353 (5), 10.4232 (6), 17.4154 (11) 
V (Å
3
)                 1331.53 (15) 
Z                 4 
Radiation type                 Mo Kα 
µ (mm
−1
)                 0.25 
Crystal size (mm)                 0.58 × 0.42 × 0.09 
No. of measured, 
independent and 
observed [I > 2σ(I)] 
reflections 
                   6852, 3292, 2422  
Rint                  0.094 
(sin θ/λ)max (Å
−1
)                 0.667 
Refinement 
R[F
2
 > 2σ(F2)], 
wR(F
2
), S 
0.049, 0.107, 0.93 
No. of reflections               3292 
No. of parameters                169 
No. of restraints                 0 
H-atom treatment           H atoms treated by a mixture of independent and constrained       
refinement 
Δρmax, Δρmin (e Å
−3
)               0.41, −0.29 
Absolute structure            Flack x determined using 751 quotients [(I+)-(I-)]/[(I+)+(I-)] 
(Parsons, Flack and Wagner, Acta Cryst. B69 (2013) 249-259). 
Absolute structure 
parameter 
              0.09 (13) 
 
 
Computer programs: SHELXL2014/7 (Sheldrick, 2014). 
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Chapter 3 
In Vitro Cytotoxicity Testing 
 
3.1 Introduction 
 
The success and limitations of cisplatin have sparked a considerable interest and research in 
the search for improved platinum-based drugs for the use of chemotherapeutic agents. 
Metallointercalators has been considered as one of the potential replacement, simply because 
they have shown to be active against cancer at much lower concentrations than cisplatin and 
they are also effective against cisplatin–resistant cancer cell lines.1 The phenanthroline-based 
platinum complexes have shown reasonable cytotoxicity against an L1210 mouse leukaemia 
cell line. Even though the metallointercalors are thought to be very active against cancer, 
ancillary ligands do have some effect on the activity of the complex. N-N-di(alkyl)-N’-
acylthioureas are thought to be an excellent ancillary ligand.
2
 
It is therefore expected that this class of [Pt (diimine)(L
n
-O,S)]Cl complexes to have activity 
against cancer because these complexes have structural features which allow for binding to 
the DNA in a number of ways which include DNA binding via the major / minor grooves or 
by partial intercalation.
1
 The activity of these complexes may be assessed by various assays 
that provide information on cellular activity. One common method for screening potential 
anticancer activity is a simple MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide).  The MTT is a colorimetric assay which measures the reduction of the 
yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by 
mitochondrial succinate dehydrogenase.
3
 The MTT enters the cell and passes into the 
mitochondria where it is reduced to an insoluble, coloured (dark purple) formazan product. 
The cells are then solubilized with an organic solvent (e.g isopropanol) and released; 
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solubilised formazan reagent is measured spectrophotometrically. Since the reduction of 
MTT can only occur in metabolically active cells, the level of activity is a measure of the 
viability of the cells. The MTT is widely used in cytotoxicity studies for screening new 
anticancer compounds, due to its accuracy and relative simplicity. It is worth noting though 
that the MTT does not provide any information on the molecular mechanism of the cytotoxic 
activity of the drug.
3
 
This chapter describes the pre-screens (2 doses) testing of all the complexes synthesised in 
this study for in vitro cytotoxicity. The testing was done at University of the Witwatersrand 
medical school by Dr Lionie Harmse using the MTT assay and was tested against the H1975 
lung cancer cells. This cell line carries a double mutation that harbours the epidermal growth 
factor receptor (EGFR(T790M)) ,where the T790M mediates resistance to EGFR inhibitors 
by acting as a “gatekeeper” mutation bringing about the steric hindrance in the Adenosine 
Triphosphate (ATP) –binding pocket and preventing inhibitor binding. 
3.2 MTT Assay to probe cytotoxicity 
 
The standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was used 
to assess the cell metabolic activity of the series of [Pt(diimine)(L
n
-O,S)]Cl complexes whose 
synthesis is described in Chapter 2. The experiments were carried out in 96 well plates with 8 
rows and 12 columns and all addition and serial dilutions were made by hand using a multi-
channel pipette. The cells were incubated overnight at 37 °C in 5% CO2 for attachment. 
Thereafter, the cells were treated with MTT, and further incubated for 2 to 4 hours until 
purple precipitate visible. The cells were then solubilised with an organic solvent 
(isopropanol) and the plates were left out at room temperature in the dark for 2 hours. The 
absorbance was recorded at 570 mm. Each sample was assayed at least four times. The 
cytotoxicity index was determined using the untreated cells as negative control. The cell 
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viability was calculated using a background-corrected absorbance according to the following 
equation: 
% cell viability = 
(1−𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑤𝑒𝑙𝑙𝑠)
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑤𝑒𝑙𝑙𝑠
 × 100 
 
The resultant plates of the compounds tested are shown in Figure 3.1.  
 
 
 
Figure 3.1: The 96 well plates of the compounds tested with MTT assay at 50 µM (left) and 
5µM (right). Refer to the table 3.1 and 3.2 in the experimental section. 
Blank 
 
[Pt(phen)(L1-O,S)]Cl 
 [Pt(phen)(L
3-O,S)]Cl 
 
[Pt(phen)(L4-O,S)]Cl 
 
[Pt(5,6-phen)(L4-O,S)]Cl 
 
[Pt(5,6-phen)(L3-O,S)]Cl 
 
[Pt(dpq)(L1-O,S)]Cl 
 [Pt(dpq)(L
3-O,S)]Cl 
 
[Pt(5,6-phen)(L1-O,S)]Cl 
 
[Pt(dpq)(L4-O,S)]Cl 
 
5 µM 50  µM 
Inactive 
Highly 
active 
                                                HL1 
                                                      HL2 
50 µM 
50 µM 
65 
 
The dark purple on the first row and first column indicate the negative blank while the others 
are for all the complexes that were tested at 50µM and 5µM respectively.  
 
3.3 Results and Discussion  
 
The results of this study show that all the [Pt(diimine)(L
n
-O,S)]Cl complexes are highly  
cytotoxic to H1975 lung  cancer cell line at 50µM. It is clear from Figure 3.1 that these 
complexes were highly cytotoxic at 50 µM such that all the cancer cells were dead after 48 
hours. Interestingly, even at lower concentrations (5 µM), the complexes still showed more 
than 50% cell death against the H1975 cancer cell lines as shown in Figure 3.2 
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Figure 3.2: MTT assay results for compounds tested with MTT assay and the % cell viability 
at 5 µM. 
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The 5,6–dimethyl phenanthroline (dmp) based platinum complexes on the other hand still 
showed almost similar cytotoxicity at 5 µM  when compared to 50 µM as early as 12 hours of 
incubation. 
On the other hand, all the dpq complexes had some serious solubility problems; it is therefore 
very difficult to use these results to fully explain the structural activity relationship. 
Nevertheless, we can clearly see that the dpq complexes are not as active which is probably 
attributed to poor solubility. However, if we consider other complexes which water solubility 
was also a problem but much better than the dpq complexes we can clearly see that the dmp 
complexes are much more active and this is possibly due to the fact that the methyl-
substituted 1,10-phenanthroline bind more strongly to the DNA than the 1,10-phenanthroline, 
due to the strong hydrophobic interaction of the methyl-substituted ligand with DNA 
surface.
4
 The 5,6-dimethyl groups are thought to be involved in  hydrophobic interaction with 
the hydrophobic DNA surface leading to enhancement in DNA binding affinity suggesting 
that the 5,6-dimethyl groups might interact in the groove of the DNA.
5
 
It has been established by Ganot and co-workers that the [Ru(NH3)(diimine)]Cl  complexes 
where the diimine = bipyridine(bpy); 1,10-phenanthroline (phen) etc, interact with DNA 
through their diimine face, which is supported by the hydrogen bonding.
4
 In addition, if the 
diimines in these complexes are di/ tetra methyl-substituted-1,10-phenanthroline, the DNA 
binding affinities are higher than those with just 1,10-phenanthroline  and  bipyridine co-
ligand because the methyl substituted ligands enhances hydrophobic interaction with DNA 
leading to the release of water molecules of solvation entropically favouring the formation of 
the DNA- bound complex. 
When trying to further establish the structure-activity relationships, the ligands were assayed. 
It was found that the acetyl thioureas was least cytotoxic than the benzoyl and pivaloyl 
68 
 
variations in the complexes, which proved that these ancillary ligands are not completely 
acquitted because they do affect the activity of the complexes. These ligands were then tested 
alone and they showed to have some activity even though it only inhibited 20% of the cell 
growth; nevertheless, this clearly indicates that the ligands themselves have some activity 
against H1975 cancer cell lines. 
3.4 Conclusion 
 
It was found that all the [Pt(diimine)(L
n
-O,S)]
+
 complexes displayed significant activity 
against H1975 lung cancer cell lines at 50 µM and at 5 µM. The complexes containing 
methyl substitution at the 5 and 6 position of 1,10-phenanthroline ([Pt(dmp)(L
3
-O,S)]Cl and 
[Pt(dmp)(L
1
-O,S)]Cl) were highly cytotoxic with cell death of greater than 98% even at 5 µM  
and are expected to have low nano molar IC50 values. However, the complexes that contained 
the pyrazine group were found to be the least active which was attributed to the low solubility 
of these complexes. Currently, the IC50 of these complexes are still being determined, which 
will give sufficient information to carefully consider the structural activity relationship. 
Furthermore, the testing of these complexes will be extended to 4 cancer cell lines and 
mechanistic studies will be are conducted. 
The poor water solubility of these complexes remains one of the major challenges when 
considering them as potential anticancer agents. Variations of the ancillary ligand have 
proved to improve solubility. However, for some of the diimine ligands especially dpq, 
solubility was not improved and we have to consider drug delivery system in an attempt to 
address this problem. 
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3.5 Experimental Section  
 
The percentage of the activity of the compounds tested for MTT assay at 50 µM and 5 µM is 
shown Table 3.1 & 3.2 with their average mean of cell viability percentage: 
Table 3.1: Percentage cell viability of compound tested with MTT assay at 50µM, along with 
the average mean and standard error 
                  
                
 % cell viability at 50 µM 
H1975 cells 
 
 
Trial 1 Trial 2 Trial 3 Trial 4 Average%      
[Pt(phen)(L
1
-O,S)]Cl 1.7 2.0 2.2 2.2 2.0 ± 0.1 
[Pt(phen)(L
3
-O,S)]Cl 0.2 0.3 0.7 1.0 0.6 ± 0.2 
[Pt(phen)(L
4
-O,S)]Cl 2.5 2.7 2.0 3.4 2.7 ± 0.3 
[Pt(5,6-phen)(L
1
-O,S)]Cl 1.1 0.9 0.7 1.6 1.1 ± 0.2 
[Pt(5,6-phen)(L
3
-O,S)]Cl 1.7 2.1 1.9 1.6 1.8 ± 0.1 
[Pt(5,6-phen)(L
4
-O,S)]Cl 1.1 1.4 0.9 0.9 1.1± 0.1 
[Pt(dpq)(L
1
-O,S)]Cl 2.3 2.5 2.1 1.5 2.1 ± 0.2 
[Pt(dpq)(L
3
-O,S)]Cl 0.6 1.0 0.9 0.3 0.7 ± 0.1 
[Pt(dpq)(L
4
-O,S)]Cl 0.6 1.6 0.7 1.1 1.0 ± 0.2 
N,N-di(butyl)-N’-benzoylthiourea 67.2 67.9 71.7 75.2 70.5 ±1.6 
N,N-di(hydroxy)-N’-benzoylthiourea  90.6 88.8 89.0 89.9 89.6 ± 0.37 
N,N-di(butyl)-N’-pivaloylthiourea 77.2 74.1 74.4 73.4 74.8 ± 0.7 
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Table 3.2: cell viability of compound tested with MTT assay at 5µM, along with the average 
mean and standard error 
 
 
 
 
    
 
 
    
[Pt(phen)(L
1
-O,S)]Cl 21.1 23.9 18.5 19.0 20.6 ± 1.60 
[Pt(phen)(L
3
-O,S)]Cl 38.5 46.4 57.6 55.8 49.6 ± 3.8 
[Pt(phen)(L
4
-O,S)]Cl 14.9 15.9 21.5 19.6 18.0 ± 1.4 
[Pt(5,6-phen)(L
1
-
O,S)]Cl 
16.5 16.0 17.4 16.3 16.6 ± 0.3 
[Pt(5,6-phen)(L
3
-
O,S)]Cl 
2.8 2.2 2.8 3.3 2.8 ± 0.2 
[Pt(5,6-phen)(L
4
-
O,S)]Cl 
0.0 0.1 0.0 0.0 0.0 ± 0.0 
[Pt(dpq)(L
1
-O,S)]Cl 33.4 43.4 46.1 50.7 43.4 ± 3.1 
[Pt(dpq)(L
3
-O,S)]Cl 29.6 40.5 36.8 31.5 34.6 ± 2.1 
[Pt(dpq)(L
4
-O,S)]Cl 20.5 25.1 22.5 16.1 21.1 ± 1.7 
 
 
 
 
 
 
 
% cell viability at 5 µM 
H1975 cells 
      Trial 1            Trial 2             Trial 3                Trial 4                Average 
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Chapter 4 
Encapsulation of the [Pt(diimine)(L-O,S)]
+
 complexes with the 
Drug-delivery systems. 
4.1 Introduction 
 
The [Pt(diimine)(L-O,S)]
+
 complexes have been found to be highly active against the H1975 
lung cancer cell line (in vitro). However, one major drawback of [Pt(diimine)(L-O,S)]
+
 as 
potential metallodrugs is their poor solubility, which has an effect on the anticancer activity 
as shown in chapter 3. The strategy to address this problem of poor solubility typically 
involves the use of drug-delivery systems such as cyclodextrins, liposomes or micelles to host 
potential anticancer drugs. Furthermore, smart drug delivery systems have the ability to not 
only improve the delivery and effectiveness of metallodrugs but also can sometimes reduce 
the cytotoxicity and improve drug metabolism.
1
 Functionalised cyclodextrin such as 
sulphurbutyl-β-ether cyclodextrin (Captisol) have been widely used in the early stages of 
pharmaceutical application because of its commercial availability and cavity size suitable for 
the wide range of drugs.
2
 Captisol is made of a hydrophilic exterior and hydrophobic interior 
which makes it possible for water-insoluble drugs to insert into the hydrophobic cavity via 
non-covalent association to the captisol which results in a host-guest complex with improved 
water solubility.
3
 Wen et al. were able to show that the β-cyclodectrins can improve the 
solubility of Carvedilol({1-[carbazolyl-(4)-oxy]-3-[2-methoxyphenoxyethylamino]propanol-
(2)}) compound, where he found that the guest solubility increases linearly with cyclodextrin 
concentration inferring the formation of a soluble inclusion complex between the drug and β-
cyclodextrin.
4
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Micelles have also shown to be excellent drug delivery vehicles. This stems from their unique 
structural composition, which is characterised by a hydrophobic inner cavity sterically 
stabilised by a hydrophilic outer surface. The former serves as a reservoir in which the drug 
molecule can be incorporated by means of chemical, physical or electrostatic interaction, 
depending on their physicochemical properties. The utility of micelles in the field of drug 
delivery is based on their characteristic self-assembly into core-shell nanostructure in 
aqueous solutions. Hence, its formation is not dependent on the drug molecules as other drug 
delivery systems and could potentially deliver a large variety of therapeutic compounds. 
Another  advantages of using micelles as a drug delivery system is other than solubilizing the 
drug, they can also target their payload to specific tissues through either passive or active 
means. They can employ biologically inert macromolecules to direct the drug to its target site 
in the body. 
Micelles can be subdivided into two different groups according to their molecular weight: 
low- molecular -weight surfactant micelles and polymeric micelles.
5
 We opted for using both 
low-molecular–weight surfactant micelles specifically polysorbate 80 (Tween 80), 
polysorbate 85(Tween 85) and polymeric micelle namely poloxamer 407. Tween 80 has been 
used to solubilize different anticancer drugs including cisplatin, docetaxel, etoposide, 
paclitaxel, carcelesin , bisnatide derivates and several photosensitizers.
5
 Furthermore, Tween 
80 is biologically active and pharmacologically compatible. Poloxamers known as 
polyethylene-propylene glycol polymer has been well known for its diverse pharmaceutical 
applications.
6
 
This chapter describe the attempt to encapsulate of [Pt(diimine)(L-O,S)]
+
 in sulphobutyl-
ether-β-cyclodextrin (captisol) and low-molecular-weight surfactant micelles. The inclusion 
complexes were characterized by 
1
H-NMR and DOSY NMR Spectroscopy.  
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4.2 Encapsulation of [Pt(diimine)(L-O,S)]
+
complexes with captisol 
 
There are several methods for the synthesis of cyclodextrin–guest complexes depending on 
the physical properties of the guest molecules. These methods include: kneading, 
neutralisation, grinding, co-precipitation and lyophilization.  The different methods were 
attempted in order to encapsulate the complexes (see Experimental Section 4.3). The method 
that seemed to work best was method 2 which involves a solution of complex and captisol 
(one mole equivalence) in MeOH, heating under reflux for 3 hours, followed by stirring 
overnight at room temperature. The solvent was removed by rotary evaporation and the 
product was left to dry in the fumehood. In order to ascertain the structure of the inclusion 
complex, 
1
H NMR Spectroscopy studies of the free complex; free captisol and inclusion 
complex were therefore undertaken.  
4.2.1 
1
H-NMR Spectroscopy studies of inclusion complex formation 
 
Sulphurbutyl-β-ether cyclodextrin (captisol) is generally known to have primary and 
secondary OH groups crowning opposite ends of its torus, where 3 hydrogens are located on 
the exterior of the cyclodextrin and 2 hydrogens are located on the interior with one hydrogen 
on the edge of the cyclodextrin as shown in Figure 4.1.
7
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Figure 4.1: Representation of the structure of captisol. 
If inclusion complexation took place, we expected that the protons located on the interior 
should be strongly shielded due to the anisotropy of the aromatic moiety, while the protons 
on the exterior should not be affected. However, this cannot be observed in this case since the 
protons on the interior will exchange with MeOD. Furthermore, where inclusion does not 
take place but rather adsorption or ion-pairing, then the protons on the exterior should be the 
most affected. 
The NMR characteristic protons of the complexes and the protons of the cavity of captisol are 
different; hence one is able to monitor the interaction between the complex and captisol. 
Significant shifts were observed on the aromatic protons of the free complex and inclusion 
complex as shown in Figure 4.2 and summarised in Table 4.1. 
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Table 4.1: NMR chemical shift difference between the free complex and the mixture between 
complex and captisol. 
Complex Inclusion complex Δδ 
   
H1&8 (9.11) H1&8 (8.86) 0.25 
H3 (9.06) H3 (8.62) 0.44 
H6 (8.84) H6 (8.35) 0.49 
H2 (8.21) H2 (8.00) 0.21 
H7 (7.98) H7 (7.80) 0.18 
 
All the protons on the aromatic group experienced a shielding effect, after encapsulation as 
shown in Figure 4.2 (a) and (b). 
 
 
 
(a) 
Free Complex 
Inclusion Complex 
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Figure 4.2: (a) The full spectrum 
1
H NMR of the free complex (top) and inclusion complex 
(bottom). (b) Aromatic region of the free and inclusion complex. 
This uplift shift of the aromatic protons might be induced by diamagnetic anisotropy of 
particular bonds of β-cyclodextrin and van der waals shift. The OH group chemical shifts of 
captisol could not be established since the OH’s from the captisol exchanges with the OH 
from the deuterated methanol. This suggests that there might be some interaction, whether it 
is ion-pairing or encapsulation. 
 However, due to difficulties to pinpoint what is causing the changes in the chemical shifts, 
elaborate characteristics of the interaction cannot be inferred. Hence the DOSY NMR was 
used to study this, since it is independent from chemical shift changes and it is related to the 
diffusion of the molecule in solution. 
 
(b) 
Free Complex 
Inclusion Complex 
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4.2.2 DOSY NMR 
 
Diffusion-Ordered Spectroscopy (DOSY) NMR can be described as a two-dimensional NMR 
experiment, in which the signal decays exponentially according to the self-diffusion 
behaviour of individual molecules.
8
 There are two dimensions in the DOSY NMR, the first 
one is for conventional chemical shift and the second one is for diffusion dimension.
9
 The 
diffusion behaviour is dependent on the properties of an individual molecule, which include 
the size, shape, mass, charge as well as its surrounding environment, which include solution, 
viscosity, temperature and aggregation state. Due to these properties of the molecules, each 
component in a mixture can be pseudo-separated, based on its own diffusion coefficient on 
the diffusion dimension.
8
 DOSY NMR has been known for its advantages, it can be used as a 
non-invasive method for both physical and chemical information. Diffusion coefficients can 
be obtained from measuring the attenuation of the NMR signals (Figure 4.3 ) during a pulsed 
field gradient (PFG) experiment and are easy to determine using the 2D processing.
10
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Figure 4.3: Attenuation of the 
1
H NMR of the mixture of inclusion complex, methanol, water 
during a typical DOSY experiment with the increasing gradient strength (G). 
In order to explain the attenuation of the resonance signal and PFG experiment, the Scheme 
4.1 below is used. 
G 
 [Pt(diimine)(L-O,S)]
+
 
H2O 
MeOH 
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Scheme 4.1: Representation of the translation of molecule A and B. 
Hypothetically Scheme 4.1 represents the translation of the molecules A and B in z-axis 
direction. Furthermore, the molecules A diffuses faster than the molecule B during the same 
diffusion delay time interval (Δ). The experiment therefore consists of two pulsed field 
gradient (PFG) where there is a diffusion delay Δ between the two PFG’s and the second 
PFG is the inverse of the first PFG. The complete refocussing of the magnetization 
components will occur when the local magnitude field of a nucleus is identical during the two 
gradient pulses.
10
 The local magnetic field is spatially dependent because of the field gradient 
(Gz) that is used. This indicates that a molecule that diffuses at the diffusion delay between 
the two gradient pulse will experience a different local magnitude field when the second PFG 
is applied which leads to only partial refocussing of the magnetization, resulting in the 
attenuation of the resonance signal. 
 DOSY measurements are attained by means of either gradient in the main magnetic field, or 
by the gradient in radio frequency fields. The signal contribution of each component from the 
DOSY experiment is described by equation (1).
9
 
I (i,g
2
)  = IO (i) exp [ -D (i) (Δ-δ/3) K
2 
]                eq. (1) 
K = γgδ 
A B 
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where  I(i) is the signal amplitude of component i, Io(i) is the amplitude with no gradient 
applied,γ is the gyromagnetic ratio of the 1H nucleus (rad S-1T-1), g the gradient strength (T),  
δ the duration of gradient pulse (S), Δ the diffusion time (s) and D(i) is the diffusion 
coefficient of  ith component (m
2/s). In eq.(1), if Δ and δ  are the experimental constants, then 
the signal of a DOSY experiment attenuates depends on the gradient strength (g
2
) and 
diffusion coefficient (D) of individual components. In simple terms molecules in liquid or 
solution state naturally move around. This translational motion is in contrast with rotational 
motion, known as Brownian molecular motion and is often called diffusion or self-
diffusion.
11
 Assuming a spherical size of the molecule, the diffusion coefficient D is 
described by the Stokes-Einstein equation: 
D = kT/6πƞγs                                                      eq.(2) 
where k is the Boltzmann constant , T is the temperature ,Ƞ the viscosity of the liquid and γs, 
is the (hydrodynamic) radius of the molecule. A least-square fit of the equation 1 to the signal 
attenuation data allows for the calculation of diffusion coefficient, D. The calculated 
diffusion coefficients are displayed as a 2D- plot as shown below. 
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Figure 4.4: DOSY plot of a mixture of [Pt(dmp)(L
3
-O,S)]
+
, methanol and water showing the 
diffusion coefficients. 
Captisol has the molecular weight of 2163g/mol while the molecular weight of the complexes 
range from 604g/mol to 718g/mol. We therefore expect the inclusion complex to have a 
smaller diffusion coefficient as compared to the diffusion coefficient of the free complex and 
captisol. Interestingly the opposite was observed even in the cases where the concentration of 
captisol was changed. The diffusion coefficient of the inclusion complex was found to be 
larger than that of the free complex and the free captisol. This clearly suggests that the 
encapsulation was not successful. Furthermore, when the concentration of the complex was 
increased, similar results were observed as shown in Table 4.2.  
 
Methanol 
Complex 
Captisol 
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Table 4.2: The Diffusion Coefficients of the inclusion complexes. 
 Complex ratio   : Captisol  Diffusion coefficient 
MeOH 
[Pt(dmp)(L
3
-O,S)]
+
only 
 2.058x10
-9
 
 3.495x10
-10
 
Captisol only  2.906x10
-10
 
Mixture 1 2:1 3.970x10
-10
 
Mixture 2 1:1 3.911x10
-10
 
Mixture 3 1:2 3.556x10
-10
 
 
Having the unexpected results from the 
1
H NMR  and DOSY NMR, preliminary solubility 
studies were performed to get more information on whether the inclusion complexation took 
place or not. When the solubility studies were performed on the inclusion complexes, it was 
observed that they were less soluble as compared to the free complexes. What was expected 
was if the inclusion complexation was successful the inclusion complexes should be very 
soluble in aqueous solvents. Captisol’s solubility in water is greater than 1500mg/ ml, which 
means that if the encapsulation was successful then the inclusion complex should be soluble 
in water. This was found not to be the case, in addition, even when the concentration of 
captisol was increased still the solubility was still low, suggesting that the complex might be 
aggregating in solution as observed by Kotzé et al.
12
 Furthermore, the captisol might also be 
aggregating in methanol and/or ion-pairing with the complex to yield a less soluble product. 
 Usually, complexation with captisol typically occurs best with neutral molecules. However, 
many cationic complexes have shown to complex well with captisol because of the 
electrostatic interaction between the charges. The complexes are cationic and hence what was 
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expected was the presence of the positive charge on the drug can assist inclusion 
complexation via charge attraction. With all the information gathered it was evident that the 
complexes were not encapsulated. Micelle formation as a drug delivery system was then used 
as an alternative in attempt to address the solubility problem. 
  
4.2.3 Micelles as a drug-delivery system  
 
Similarly to the cyclodextrin, the micelles possess the characteristic of having a hydrophobic 
core sterically stabilized by a hydrophilic corona.
13
 We opted for using both low-molecular –
weight surfactant micelles specifically polysorbate 80 (Tween 80), polysorbate 85(Tween 85) 
and polymeric micelle namely poloxamer 407.  
4.2.3.1 Encapsulation of [Pt(diimine)(L-O,S)]
+
complexes in Micelles 
 
Two methods of encapsulating the complex in the micelles were explored in attempt to form 
the micelles. The first method included dissolving polyoxyethylene- polypropylene block 
copolymer (poloxamer 407), polyoxyethylene sorbitanmonostearatte (Tween 80), 
polyoxyethylene sorbitantrioleate (Tween 85) in water at the concentration of 5%(w/v).  An 
excess of [Pt(phen)(L
1
-O,S]
+
 was added to obtain a saturated micellar solution and 
magnetically stirred overnight at room temperature. The [Pt(phen)(L
1
-O,S]
+
 complex was 
used for this study because it is easy to made but relatively insoluble. Afterwards, the 
resulting saturated solution was filtered in order to room any insoluble complex. The second 
method was based on dissolving the Tween 80 and Tween 85 in water. A one mole 
equivalent of the [Pt(phen)(L-S,O)]
+
 was then added. The reaction was magnetically stirred 
for 24 hours. The solvent was removed by rotary evaporation to yield the product. 
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When the preliminary of the products was tested in water, they were found to form stable 
colloidal solution, suggesting that possibly aggregation is not taking place but rather 
encapsulation is taking place to some extent . Even though this was not the desired results, 
but it was a good indication that the micelles can be used as a drug delivery systems for these 
complexes. 
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4.3 Experimental Section 
4.3.1 Instrumentation and Material 
 
All the reagents were commercially available and used as received. The captisol was kept in a 
sealed container with desiccants in order to avoid any contact with the moisture from the air. 
The 
1
H NMR and DOSY experiments were recorded on a Bruker Avance III 500MHz. The 
DOSY experimental parameters were as follows: 
1
H spectral width 14.0019ppm; Number of 
acquisitions varied from the sample; Recycling delay 2s; Diffusion delay 30ms and Gradient 
pulse duration 2ms. 
4.3.2 Sample preparation for DOSY Spectroscopy 
 
The DOSY experiments were done in 5mm tubes, where the inclusion complexes were 
dissolved in respective solvents to obtain the desired concentration. The samples were left in 
the spectrometer for about 10 to 15 minutes in order to make sure that there was temperature 
equilibrium before the measurements were done. 
4.3.3 Methods of encapsulating the drug with the Captisol 
 
Method 1 
A solution of [Pt(phen)(L-O,S)]
+
( 10mg), captisol (1 mole equivalent) and NaCl (1.5 mole 
equivalent ) in H2O (20 ml) was heated under reflux for 6 hours, then stirred overnight at 
room temperature. The solvent was removed by rotary evaporation to yield the product as a 
yellow solid. 
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Method 2 
[Pt(phen)(L-O,S)]
+
 (4mg) and captisol (1 mole equivalent) in MeOH was heated under reflux 
for 3 hours, and then stirred overnight at room temperature. The solvent was removed by 
rotary evaporation and the mixture was left to dry in the fume hood overnight. 
Method 3 
A mixture of [Pt(phen)(L-O,S)]
+ 
(10mg) in MeOH and  (16.72mg) of captisol in H2O 
(50mL),was heated for 3 hours and left to stir overnight at room temperature. The two solvent 
layers were isolated and the solvent from each layer was removed by means of the rotary 
evaporator and the product from each layer was dried under vacuum. 
Method 4 (Physical Mixtures) 
A 20mg sample of solid containing [Pt(phen)(L-O,S)]
+
 and 1 mole equivalent of captisol was 
blended in a mortar and pestle until a homogeneous mixture was obtained . 
Method 5 (Lyophilization) 
The inclusion complex was prepared by the lyophilisation method. The aqueous solution of 
[Pt(phen)(L-O,S)]
+
 inclusion complex was prepared by dissolving 10mg of [Pt(phen)(L-
O,S)]
+
 and 17.6mg of captisol in 50mL ethanol. The reaction mixture was heated under reflux 
for 6 hours and stirred at room temperature overnight. The resultant solution was the 
subjected to freeze-dying for about 48 hours to obtain a yellow powder. In this method, 
different molar equivalence was considered, where at some cases the [Pt(phen)(L-O,S)]
+
 
complex was in excess and in some cases, the captisol was in excess. 
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4.3.4 Methods of micellar formation 
 
To a glass polytude , 3.99 mg of Tween 80 and Tween 85 were added. 2 mg of the complex 
was added to the saturated solution. A small volume of water was further added for the 
micellar saturated solution. The mixture was stirred for 2 days at room temperature. A pale 
yellow resultant mixture was obtained and preliminary studies were done on it. In the case 
where polaxamer 407 was used, an equivalent mol of it was added along with Tween 85 and 
Tween 80 before the addition of the complex and similar results were obtained.  
 
4.4 Conclusion 
 
It was found that the captisol does not encapsulate the complexes. However, significant shifts 
were observed on the aromatic protons suggesting that there is some interaction that is taking 
place. Due to the difficulties to pinpoint what was causing the shifts on the aromatic protons, 
DOSY NMR was considered as an excellent tool to study this, which revealed that the 
encapsulation was not successful. When preliminary solubility studies were performed, they 
also showed that the encapsulation was not successful, which might have been due to the size 
of the cavity of the captisol such that the coordination compound was too big to fit in the 
cavity. 
Low-molecular-weight surfactant micelle was used as an alternative in attempt to address the 
solubility problem, which was found to show some interaction. The inclusion complex 
formed colloidal suspension suggesting that aggregation is not taking place but rather 
encapsulation is taking place to some extent. However, future studies are aimed at exploring 
the micellar formation as a drug delivery system and trying to encapsulate the complexes into 
the micelles in order to address the solubility problem.  
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Chapter 5 
 Summary and Conclusion 
 
A series of N,N-dialkyl-N’-acylthiourea ligands was successfully synthesised and 
characterised. The hydroxyl containing ligands were found to be a challenge to synthesise, 
however N,N-di(2-hydroxyethyl)-N’-acylthiourea was successfully synthesised and we report 
a crystal structure that has never been published before. The ligand exhibited intermolecular 
and intramolecular interaction and it was found to have a herringbone packing pattern. A 
series of novel mixed-ligand cationic [Pt(diimine)(L
n
-O,S)]
+ 
complexes where diimine 
represents 1,10-phenanthroline; 5,6-dimethyl-1,10-phenanthroline and [3,2-d:2’,3’-f] 
quinoxaline and (L
n
-O,S) represents various N,N-dialkyl-N’-acylthioureas were successfully 
synthesised. The synthesised ligands and complexes where characterised by FTIR 
Spectroscopy, NMR Spectroscopy, Mass Spectrometry and Elemental Analysis. 
The [Pt(diimine)(L
n
-O,S)]
+
 compounds were tested against H1975 lung cancer cell line using 
a MTT assay. The compounds were assayed at 50µM and 5µM. All the [Pt(diimine)(L
n
-
O,S)]
+
 compounds showed significant cytotoxicity with cell death of 90-98% at 50µM. 
Interestingly, the complexes containing methyl substituents at 5 and 6 position of 1,10-
phenanthroline (dmp) were found to be very cytotoxic even at 5µM and it has been shown in 
literature that this ligand system is considered a good groove binder because of its 
hydrophobicity. The [3,2-d:2’,3’-f]-quinoxaline (dpq)containing complexes were found to be 
cytotoxic at 50µM, but were least active of all the complexes at 5µM which might have 
attributed to the low solubility of these complexes. The structure activity relationship could 
not be fully established from the single concentration results and IC50 values are required 
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which form part of future study which is currently underway. However, from the screening 
results it is clear that the [Pt(dmp)(L
n
-O,S)]
+
 complexes are very cytotoxic and are expected 
to have low nano molar IC50 values. 
In addition, three ancillary ligands (HL
1
 and HL
2
, HL
3
) were assayed at 50µM and 5µM 
showed some weak cytotoxicity with less than 10% cell death. However, this proves that 
these ligands are not innocent and do have an influence on the cytotoxicity of the complexes. 
This is also evident even on the variations observed in viability percentages when the only 
the ancillary ligand is varied. Nevertheless, the problem of poor solubility of these complexes 
still remains, even though the variation of the ancillary ligands did improve the solubility of 
the complexes. The Sulphurbutyl-β-ether cyclodextrin (captisol) is a good drug delivery 
system for many drugs due to its hydrophilic exterior and hydrophobic interior which makes 
it possible for water-insoluble drugs to insert into the hydrophobic cavity. However, the 
solubility of [Pt(diimine)(L
n
-O,S)]
+
 did not improve even though the 
1
H NMR spectra 
suggested significant changes in the chemical shift  of the aromatic proton of the complex 
which suggest some interactions or aggregation. All the protons on the aromatic group 
suddenly experience a shielding effect after encapsulation which might have attributed to 
diamagnetic anisotropy of particular bonds of β- cyclodextrin. These shifts indicated some 
sort of interaction between the complex and captisol but that was not sufficient information to 
conclude whether the complex is encapsulated or not. DOSY NMR was found to be an 
excellent tool to study this since it does not depend on the chemical shift but rather the 
diffusion properties of the molecule in the solvent. 
It was expected that if encapsulation was successful, the diffusion coefficient of the complex 
and captisol should be equal (for stable inclusion complex) or at least smaller than the 
diffusion coefficient of the free molecules (for a fast exchange system). The DOSY NMR 
clearly suggested that the encapsulation was not successful in methanol and solubility studies 
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revealed that the aqueous solubility did not improve. Therefore the low-molecular-weight 
micelles (Tween 80 and Tween 85) were considered as a drug delivery system in attempt to 
improve solubility. Preliminary solubility studies were investigated on the inclusion complex 
upon micellar formation and it was found that the complexes are not completely soluble but 
rather form a stable colloidal suspension which suggests that this micellar formation can 
possibly be used as a drug delivery system for these complexes.  
Future studies are aimed at exploring the micellar formation as a drug delivery system, and 
trying to encapsulate the complexes into the micelles in order to address the problem of 
solubility. Future investigations also include expanding the in vitro cytotoxicity testing to 
four cancer cell lines, establish the IC50 values and do mechanistic studies to explain the 
cytotoxicity observed. Furthermore, binding between [Pt(diimine)(L
n
-O,S)]
+
 complexes and 
the DNA will be studied to establish whether the complexes interact with DNA via 
intercalation or groove binding. 
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NMR Spectroscopy 
 
1
H NMR spectrum of HL
2
 in DMSO-d6 at 25 °C. 
 
1
H NMR spectrum of HL
1
 in DMSO-d6 at 25 °C. 
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1
H NMR spectrum of HL
3
 in DMSO-d6 at 25 °C. 
 
1
H NMR spectrum of [PtCl2(1,10-phenanthroline)]in DMSO-d6 at 25 °C. 
 
1
H NMR spectrum of [PtCl2(5,6-dimethyl-1,10-phenanthroline)]in DMSO-d6 at 25 °C. 
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1
H NMR spectrum of [PtCl2(pyrazino(2,3-f)(1,10-phenanthroline)]in DMSO-d6 at 25 °C 
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Mass Spectrometry 
 
 
Mass Spectroscopy spectrum of [PtCl2(1,10-phenanthroline)]. 
  
 
 
Mass Spectroscopy spectrum of [PtCl2(5,6-dimethyl-1,10-phenanthroline)]. 
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Mass Spectroscopy spectrum of [PtCl2(pyrazino(2,3-f)(1,10-phenanthroline)]. 
 
 
 
Mass Spectroscopy spectrum of [Pt(dmp)(L
3
-O,S)]Cl. 
 
 
Mass Spectroscopy spectrum of [Pt(dpq)(L
1
-O,S)]Cl. 
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Mass Spectroscopy spectrum of [Pt(dpq)(L
3
-O,S)]Cl. 
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FTIR Spectroscopy 
 
FTIR Spectroscopy spectrum of [PtCl2(1,10-phenanthroline)]. 
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FTIR Spectroscopy spectrum of [PtCl2(5,6-dimethyl-1,10-phenanthroline)]. 
 
FTIR Spectroscopy spectrum of [PtCl2(pyrazino(2,3-f)(1,10-phenanthroline)]. 
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